<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        0803210588
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        1983
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        DEPO MEDROL VIAL 40MG-ML SAS
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        METHYLPREDNISOLONE
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        40
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        mg/ml
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Intravenous use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Suspension for injection
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        2
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        1
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Vial
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        NCE
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        36
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 30°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        19.55
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="PFIZER" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            PFIZER
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 360]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            Farouk, Maamoun Tamer & CO
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            PFIZER
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        H02AB04
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>This medicine contains methylprednisolone acetate.</p><p>&nbsp;</p><p>Methylprednisolone acetate belongs to a group of medicines called glucocorticoids. Methylprednisolone inhibits local inflammatory symptoms (heat, swelling, pain, redness) and allergic reactions (hypersensitivity). It influences many organs and metabolic processes in the body.</p><p>&nbsp;</p><p>It is therefore used to treat many conditions, such as:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Rheumatic disorders of various origins;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Tendonitis;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Allergic conditions, such as asthma, allergies to medicines;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Skin conditions;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Eye disorders of allergic or inflammatory origin;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Certain types of gastrointestinal inflammation;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Certain respiratory tract disorders;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Certain severe blood diseases;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Impaired function of the adrenal cortex.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Do not use this medicine</strong></p><p>&nbsp; If you are allergic to methylprednisolone acetate or one of the other ingredients that are in this medicine (listed in Section 6);</p><p>&nbsp; In the event of mycosis (infection of the body by a microscopic fungus);</p><p>&nbsp; Depo-Medrol must not be given by intravenous, intrathecal or epidural administration;</p><p>&nbsp; Depo-Medrol also must not be injected into the eye or nose, nor other injection sites (scalp, throat, sphenopalatine ganglion).</p><p>&nbsp;</p><p><strong>Warnings and precautions</strong><strong> </strong></p><p>Talk to your doctor or pharmacist before using Depo-Medrol:</p><p>&nbsp; If you have diabetes: Depo-Medrol may increase your need for insulin or other antidiabetics (which lower blood sugar).</p><p>&nbsp; If you have hypothyroidism, because Depo-Medrol will have a stronger effect.</p><p>&nbsp; If you have an overactive thyroid gland (hyperthyroidism).</p><p>&nbsp; If you have hypertension (your blood pressure is too high): it may get worse.</p><p>&nbsp; If you have a thromboembolic disorders (blood clots that obstruct the blood vessels).</p><p>&nbsp; If you have heart disease: you must have medical check-ups on a regular basis.</p><p>&nbsp; If you have a stomach ulcer or certain digestive diseases, such as ulcerative colitis (inflammation of the colon) or diverticulitis (inflammation of small sacs &ndash; hernias &ndash; in the colon wall): your disease may get worse. Treatment with this medicine may mask peritonitis (inflammation of the abdominal membrane) or other symptoms associated with gastrointestinal disorders such as intestinal perforation or obstruction or inflammation of the pancreas.</p><p>&nbsp; If you have recently undergone intestinal anastomosis (a type of intestinal surgery).</p><p>&nbsp; If you have had significant digestive disorders.</p><p>&nbsp; If you have already suffered from psychiatric problems such as emotional instability or have psychotic tendencies: these problems may get worse.</p><p>Talk to your doctor if you have psychological symptoms during the treatment, in particular if you are depressed or have suicidal thoughts. Psychiatric disorders can occur at the time of or directly after a dose reduction or discontinuation of this type of drug.</p><p>&nbsp; If you have a severe muscle weakness (such as asmyasthenia gravis): your disease may get worse.</p><p>&nbsp; If you have epilepsy: you must have medical check-ups on a regular basis.</p><p>&nbsp; If you have bone decalcification (osteoporosis): your disease may get worse.</p><p>&nbsp; If your kidneys do not function well (renal insufficiency).</p><p>&nbsp; if you suffer from scleroderma (also known as systemic sclerosis, a connective tissue autoimmune disease), as an increased incidence of scleroderma renal crisis has been reported with the use of corticosteroids.</p><p>&nbsp; If you have herpes simplex or shingles in the eye: there is a risk of corneal perforation with this medicine.</p><p>&nbsp; If you have or have had tuberculosis: this medicine can reactivate the disease.</p><p>&nbsp; If you have or have had prolonged or active infections: this medicine decreases your immune defence and in certain cases may worsen your disease. It may make you more susceptible to infections such as chickenpox or measles.</p><p>&nbsp; If prolonged treatment with this medicine is necessary, because regular tests are necessary.</p><p>&nbsp; If you absolutely must be vaccinated: the administration of vaccines with live or live attenuated viruses is not recommended. Depending on the type of vaccine, it may be dangerous and cause an infection, or it may be ineffective and you will not have acquired any protection from the disease. Always warn the person who is going to vaccinate you that you are being or have been treated with Depo-Medrol. Read the section &ldquo;Other Medicines and Depo-Medrol&rdquo; for more detailed information on vaccines.</p><p>&nbsp;</p><p>Contact your doctor in case of blurred vision or other visual disorders.</p><p>&nbsp;</p><p>Tell your doctor:</p><p>&nbsp; If you need to have a test: Certain results (such as measurement of thyroid hormone levels) may give false results if you are taking Depo-Medrol.</p><p>&nbsp; If you are under unusual stress: your doctor might increase the dose of your medicine for this stressful period of time to maintain its effectiveness.</p><p>&nbsp; If you need anaesthesia, the anaesthetist must be informed about your treatment with Depo-Medrol.</p><p>&nbsp; If, after a Depo-Medrol injection, pain increases significantly, you notice swelling at the injection site, joint flexibility decreases, or you get fever or malaise, contact your doctor immediately.</p><p>&nbsp; Tell your doctor before the treatment if you have a tumour of the adrenal gland (known as a pheochromocytoma).</p><p>&nbsp;</p><p>Despite improved joint symptoms after treatment, avoid excessively using that joint. Ignoring this warning could aggravate the injuries in the joint.</p><p>&nbsp;</p><p>Appropriate measures should be taken to prevent intravascular injection.</p><p>&nbsp;</p><p>Systemic corticosteroids such as Depo-Medrol should not be used in the treatment of traumatic brain injury.</p><p>&nbsp;</p><p>If you are already taking other medicines, please also read the section &ldquo;Other Medicines and Depo-Medrol&rdquo;.</p><p><em>&nbsp;</em></p><p>Tumour lysis syndrome can occur when corticosteroids are used during cancer treatment. Tell your doctor if you have cancer and have symptoms of tumour lysis syndrome, such as muscle cramping, muscle weakness, confusion, irregular heartbeat, visual loss or visual disturbances and shortness of breath.</p><p>&nbsp;</p><p>Contact your doctor promptly if you experience muscle weakness, muscle aches, cramps and stiffness while using methylprednisolone. These can be symptoms of a condition called Thyrotoxic Periodic Paralysis which may occur in patients with an overactive thyroid gland (hyperthyroidism) who are treated with methylprednisolone. You may need additional treatment to relieve this condition.</p><p>&nbsp;</p><p>Tell your doctor if any of the above warnings applies to you, or if it did in the past.</p><p>&nbsp;</p><p><strong>Children</strong></p><p>The growth and development of newborn babies and children receiving prolonged treatment should be monitored carefully by the doctor. Delayed growth is possible during prolonged treatment.</p><p>Infants and children treated for a long period are at a particular risk for intracranial hypertension.</p><p>High doses of this medicine can cause pancreatitis in children.</p><p>&nbsp;</p><p><strong>Other medicines and Depo-Medrol</strong></p><p>Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicine besides Depo-Medrol, including medicines obtained without a prescription.</p><p>&nbsp; Non-steroidal anti-inflammatory drugs (NSAIDs, such as ibuprofen) and salicylates (pain medications like acetylsalicylic acid):<br />- Concurrent use of these medicines with Depo-Medrol increases the risk of a stomach ulcer and of bleeding in the stomach or intestines.<br />- Depo-Medrol can increase the excretion of acetylsalicylic acid via the kidneys. Discontinuing the treatment with Depo-Medrol can increase the risk of toxicity from salicylates.<br />- certain NSAIDs, such as phenylbutazone, can decrease the effectiveness of Depo-Medrol.<br />- If you have hypoprothrombinaemia (abnormally low levels of a blood clotting factor), you should be cautious when using acetylsalicylic acid during treatment with Depo-Medrol.</p><p>&nbsp; An antibacterial: isoniazid: caution is advised when using this medicine at the same time as Depo-Medrol.</p><p>&nbsp; Anticoagulants (which inhibit blood clotting): Their effect may be decreased or increased by Depo-Medrol.</p><p>&nbsp; Medicines for diabetes (insulin or oral antidiabetics): You may need a higher dose of these medicines to keep your diabetes under control when used concurrently with Depo-Medrol.</p><p>&nbsp; Diuretics (which cause you to produce more urine): increase the risk of glucose intolerance when used concurrently with Depo-Medrol and some diuretics from the thiazide group. Use of Depo-Medrol with potassium-lowering drugs (such as thiazides and similar loop diuretics) can lead to potassium deficiencies in the blood.</p><p>There is also an increased risk of potassium deficiency in the blood when using corticosteroids together with the following medicines: amphotericin B (used for certain fungal infections), xanthene or beta-2-agonists (asthma medications).</p><p>&nbsp; Medications for hypertension (abnormally high blood pressure): Administration of Depo-Medrol while on such medications can lead to a gradual loss in control of the hypertension.</p><p>&nbsp; Antiepileptic drugs (carbamazepine, phenobarbital, phenytoin) can reduce the effectiveness of Depo-Medrol.</p><p>&nbsp; Anti-infection medicines: Macrolide antibiotics (such as erythromycin, clarithromycin, troleandomycin) and antifungal medicines (antifungals in the group of drugs that includes ketoconazole and itraconazole) can increase the risk of overdosing on Depo-Medrol. Conversely, antibiotics such as rifampin can decrease its effectiveness. Quinolone antibiotics increase the risk of tendonitis.</p><p>&nbsp; Cyclosporine (immunosuppressant used after a transplant): There is an increased risk of convulsions when used concurrently with Depo-Medrol. The side effects from the two drugs may be intensified when used concurrently.</p><p>&nbsp; Medicines to treat myasthenia gravis (severe muscular weakness): co-administration of Depo-Medrol and cholinesterase inhibitors (such as neostigmine and pyridostigmine) can trigger a myasthenic crisis.</p><p>&nbsp; Heart medicines from the cardiac glycoside drug group (digoxin, for example): Their toxicity can increase when administered with Depo-Medrol.</p><p>&nbsp; Cancer drugs: Methotrexate can influence the effect of Depo-Medrol.</p><p>&nbsp; Drugs used in anaesthesia: Depo-Medrol can decrease the effect of some of these agents, in particular neuromuscular inhibitors (such as pancuronium and vecuronium). Effects on the muscles (acute myopathy) have been observed when administering high doses of corticosteroids together with this type of anticholinergic drugs.</p><p>&nbsp; Sympathomimetics, such as salbutamol (used for asthma and other conditions): Depo-Medrol can increase their effectiveness, but also their possible toxicity.</p><p>&nbsp;</p><p>The effect of Depo-Medrol may be weakened or intensified when used with medicines such as:</p><p>&nbsp; certain medicines for nausea and vomiting (aprepitant, fosaprepitant);</p><p>&nbsp; diltiazem&nbsp;(used in cases of angina pectoris);</p><p>&nbsp; certain oral contraceptives (ethinyl estradiol/norethisterone);</p><p>&nbsp; certain immunosuppressants (cyclophosphamide, tacrolimus);</p><p>&nbsp; certain antiviral drugs (indinavir, ritonavir) and pharmacokinetic enhancers (cobicistat) for the treatment of HIV. The effect of these medicines may change due to concomitant administration of Depo-Medrol;</p><p>&nbsp; aminoglutethimide (used in some cases of cancer).</p><p>&nbsp;</p><p>Vaccines:</p><p>The principle of a vaccine is to teach the immune system (the body&rsquo;s defence mechanism) to recognise a disease pathogen by giving you very small doses of this pathogen. If you later become infected by the same pathogen, your immune system will recognise it and eliminate it.</p><p>Glucocorticoids slow or even block your immune system, which is then no longer able to recognise the pathogen contained in the vaccine:</p><p>&nbsp; If the doses of Depo-Medrol you receive are high enough to block your immune system, vaccination using live or live attenuated vaccines is not indicated. It is even possible that a vaccine containing live attenuated viruses could cause an infection, which can present an immediate danger if it is not controlled by a normally functioning immune system.</p><p>&nbsp; This could be dangerous in the future if you think you are protected but the vaccine did not take effect; there is no risk of infection with vaccines that do not contain live pathogens (inactive vaccines and biogenetic vaccines), but if the immune system is too weakened, it will not learn to recognise the pathogen, and the vaccine will therefore be ineffective.</p><p>If the Depo-Medrol dose that you receive is low enough not to block the immune system, the required vaccines can be administered without any danger.</p><p>&nbsp;</p><p><strong>Depo-Medrol with food, drink and alcohol</strong></p><p>Grapefruit juice can alter the effects of Depo-Medrol.</p><p>&nbsp;</p><p>Always talk to your doctor or pharmacist about the use of alcohol when taking this medicine.</p><p>&nbsp;</p><p><strong>Pregnancy, breast-feeding and fertility</strong></p><p>If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor or pharmacist for advice before taking this medicine.</p><p><em>&nbsp;</em></p><p><em>Pregnancy</em></p><p>Use of this medicine during pregnancy is generally not recommended, unless it takes place in consultation with your doctor. If you become pregnant during treatment with this medicine, tell your doctor.</p><p>&nbsp;</p><p><em>Breast-feeding</em></p><p>Use of this medicine during breast-feeding is generally not recommended, unless it takes place in consultation with your doctor. Corticosteroid medicines pass into breast milk.</p><p><em>&nbsp;</em></p><p><em>Fertility</em></p><p>Studies in animals have shown that corticosteroids can affect fertility.</p><p>&nbsp;</p><p>Driving and using machines</p><p>Vertigo, dizziness, vision disorders and fatigue are possible side effects after treatment with corticosteroids. Vision disorders are among the rare side effects.</p><p>If you experience these problems, do not drive vehicles and/or use machines.</p><p><u>&nbsp;</u></p><p><strong>Depo-Medrol contains sodium</strong></p><p>This medicine contains less than 1 mmol (23 mg) sodium per 40 mg/1 mL and 80 mg/2 mL, meaning that it is essentially &ldquo;sodium free&rdquo;.</p><p><u>&nbsp;</u></p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Always use this medicine exactly as your doctor has told you. Check with your doctor or pharmacist if you are not sure.</p><p>&nbsp;</p><p>This medicine can only be administered by a doctor (or by a nurse for intramuscular administration). The dose to be administered and the duration of treatment depend on the disease.</p><p>Your doctor will determine how often and how long this medicine should be administered. Follow your doctor&rsquo;s recommendations precisely.</p><p>&nbsp;</p><p>Depo-Medrol can be administered in the following ways:</p><p>&Yuml;&nbsp; injection into a muscle (intramuscular injection);</p><p>&Yuml;&nbsp; injection into or near a joint (intra-articular or periarticular injection);</p><p>&Yuml;&nbsp; injection into a bursa, a small sac between attachment sites of the tendons (intrabursal injection);</p><p>&Yuml;&nbsp; injection into a skin lesion (intralesional injection);</p><p>&Yuml;&nbsp; injection into soft tissue;</p><p>&Yuml;&nbsp; enema (intrarectal instillation);</p><p>&Yuml;&nbsp; intra-articular injection.</p><p>Depo-Medrol cannot be administered by any other route than those described above.</p><p>&nbsp;</p><p><strong>If you use more Depo-Medrol than you should</strong></p><p>An acute overdose of this medicine does not cause any immediate, visible side effects. Cases of acute intoxication and/or death after an overdose of corticosteroids are rare. In the event of an overdose, there is no specific antidote; treatment consists of giving supportive care and symptom relief.</p><p>Methylprednisolone can be removed using dialysis.</p><p>&nbsp;</p><p>If you have used or taken too much Depo-Medrol, contact your doctor, pharmacist or poison control centre (070/245 245) immediately.</p><p>&nbsp;</p><p><strong>If you forget to use Depo-Medrol</strong></p><p>Since you receive this treatment under close medical supervision, it is unlikely that an injection will be forgotten. However, if you believe that is the case, tell your doctor. Do not take a double dose to make up for a forgotten dose. Take the next dose according to the usual plan.</p><p>&nbsp;</p><p><strong>If you stop using this medicine</strong></p><p>Your doctor will determine how long you must use this medicine. Medical supervision is recommended when stopping long-term treatment, and treatment should be tapered gradually. Your doctor should look out for the onset of symptoms of adrenal insufficiency such as weakness, a drop in blood pressure when you stand up after lying down, and depression.</p><p>A &ldquo;withdrawal syndrome&rdquo; may develop with the following symptoms if the treatment is ended abruptly: significant loss of appetite, nausea, vomiting, lethargy, headache, fever, joint pain, breakdown of the top layer of skin, muscle pain, weight loss and/or low blood pressure.</p><p><strong><u>&nbsp;</u></strong></p><p>Psychological effects have been reported upon stopping this type of drug. Tell your doctor if you have any psychiatric disorders during or right after stopping the treatment.</p><p>&nbsp;</p><p>If you have any further questions on the use of this medicine, ask your doctor or pharmacist.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, this medicine can cause side effects, although not everybody gets them.</p><p>&nbsp;</p><p>In rare cases, this medicine can cause a potentially fatal severe allergic reaction (anaphylactic shock). If you notice rapidly developing breathing difficulties, swelling of the face and throat, an overall feeling of illness (shock), <strong>contact your doctor immediately</strong>.</p><p>&nbsp;</p><p>In general, the risk of side effects is low if this medicine is used for a short period of time. This risk of side effects does increase at high doses over a long period.</p><p>&nbsp;</p><p>The following are the main side effects that can appear, at unknown rates (cannot be estimated from the available data):</p><p>&Yuml;&nbsp; <em>Cardiac disorders: </em>Congestive heart failure (in patients who are susceptible to it).</p><p>&Yuml;&nbsp; <em>Vascular disorders</em>: High blood pressure (hypertension) or low blood pressure (hypotension), increased blood coagulation.</p><p>&Yuml;&nbsp; <em>Blood disorders:</em> <em>Increase in white blood cells.</em></p><p>&Yuml;&nbsp; <em>Muscle and bone disorders</em>: Muscle weakness, loss of calcium in the bones (osteoporosis), delayed growth, fractures, spinal compression due to fracture, loss of muscle mass, torn tendons, in particular the Achilles tendon (between the calf and the foot), breakdown of bone, joint disorders, muscle disease (myopathy), muscle pain or joint pain.</p><p>&Yuml;&nbsp; <em>Gastrointestinal disorders</em>: Peptic ulcer with the risk of perforation and haemorrhaging, bleeding in the stomach, intestinal perforation, pancreatitis, oesophagitis (with or without ulcer), abdominal pain, bloating, diarrhoea, digestive disorders, nausea, vomiting.</p><p>&Yuml;&nbsp; <em>Hepatobiliary disorders</em>: Methylprednisolone may damage your liver. Cases of hepatitis and increase in liver enzymes have been reported.</p><p>&Yuml;&nbsp; <em>Skin disorders</em>: angioedema (allergic reaction), bruising, acne, small red spots under the skin from blood leaking into the skin (petechiae) ), stretch marks, increase (hyperpigmentation) or decrease (hypopigmentation) in the normal colour of the skin, excessive hair growth in women (hirsutism), alteration of the skin at the injection site (dermal and subdermal atrophy may cause skin depressions), rash, skin redness, itching, hives, excessive sweating.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <em>Metabolism and nutrition disorders</em>: Impaired glucose tolerance, increased need for insulin or medication to lower blood sugar levels in persons with diabetes, sodium build-up, fluid retention, loss of potassium (which can lead to hypokalaemic alkalosis), changes in blood lipid levels (dyslipidaemia), increased appetite (which can lead to weight gain), build-up of fatty tissue in various parts of the body, high blood acidity (metabolic acidosis).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <em>Ear and labyrinth disorders</em>: Dizziness.</p><p>&Yuml;&nbsp; <em>Nervous system disorders</em>: Increased intracranial pressure, seizures, memory loss, intellectual function disorders, dizziness, headache.</p><p><em>Mental health disorders:</em> Affective disorders (including depression, euphoria, unstable affect, psychological dependency, suicidal thoughts). Severe mental disorders (including euphoric exaltation, delusions, hallucination and [worsening of] schizophrenia), confusion, mental disorders, anxiety, changes in personality, mood swings, abnormal behaviour, .<br />The following symptoms occur most commonly in children: mood swings, abnormal behaviour, insomnia, feeling irritable.</p><p>&Yuml;&nbsp; <em>Hormonal disorders</em>: Obesity of the upper body with the appearance of a puffy and red face, called moon face (Cushing&rsquo;s syndrome), insufficient hormone secretion by the pituitary gland (hypopituitarism), irregular menstrual periods, steroid withdrawal syndrome (see section 3, &ldquo;If you stop using Depo-Medrol &rdquo;).</p><p>&Yuml;&nbsp; <em>Eye disorders</em>: Cataracts, glaucoma, bulging eyes (exophthalmos), rare cases of vision loss in the case of injection into a lesion in the face or head region, diseases of the retina and choroid membrane, blurred vision.</p><p>&Yuml;&nbsp; <em>Immune system disorders</em>: Allergic reactions and potentially fatal serious allergic reactions (including increased sensitivity to a foreign substance).</p><p>&Yuml;&nbsp; <em>Infections</em>: Infections, opportunistic infections (due to pathogens that are normally harmless because the immune system keeps them under control, but which may become dangerous if the immune system is no longer keeping them under control), infections at the injection site, inflammation of the lining of the abdominal cavity (peritonitis).</p><p>&Yuml;&nbsp; <em>Respiratory disorders</em>: Obstruction of a blood vessel in the lungs (pulmonary embolism), persistent hiccoughs.</p><p>&Yuml;&nbsp; <em>General conditions and administration site disorders</em>: Delayed healing, swelling (peripheral oedema), reaction at the injection site, sterile abscess (without presence of disease pathogens), fatigue, malaise.</p><p>&Yuml;&nbsp; <em>Tests and examinations:</em> Decrease in potassium, change in blood test results for liver function (alkaline phosphatase), increase in the pressure in the eye, decreased tolerance for carbohydrates, increased calcium in the urine, suppressed reactions to skin tests, increase in urea in the blood.</p><p>&nbsp;</p><p><strong>Reporting of side effects</strong></p><p>If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via national reporting system</p><p>By reporting side effects, you can help provide more information on the safety of this medicine.</p><p>&nbsp;</p><p>&nbsp;</p><p><strong>To Report side effects</strong></p><p>&nbsp;</p><ul><li>Saudi Arabia</li></ul><p>&nbsp;</p><table border="0" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>National Pharmacovigilance &nbsp;Centre ( NPC )</p><ul><li>Call center : 19999</li><li>E-mail: npc.drug@sfda.gov.sa</li><li>Website: https://ade.sfda.gov.sa/</li></ul><p>&nbsp;</p></td></tr></tbody></table>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Keep this medicine out of the sight and reach of children.</p><p>Store below 30C</p><p>&nbsp;</p><p>Do not use this medicine after the expiry date which is stated on the carton after EXP. The expiry date refers to the last day of that month.<br /><br />Shelf life 36 months.<br />&nbsp;</p><p>&nbsp;</p><p>Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>&nbsp; The active substance in this medicine is methylprednisolone acetate.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Depo-Medrol 40&nbsp;mg/1 ml contains 40&nbsp;mg of methylprednisolone acetate in 1&nbsp;ml of suspension for injection (40&nbsp;mg/ml).</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Depo-Medrol 80&nbsp;mg/2 ml contains 80&nbsp;mg of methylprednisolone acetate in 2&nbsp;ml of suspension for injection (40&nbsp;mg/ml).</p><p>&nbsp; The other ingredients in this medicine are</p><p>Macrogol 3350; myristyl-gamma-picolinium chloride; sodium chloride; water for injection (see section 2, &ldquo;Depo-Medrol contains sodium&rdquo;).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                Depo-Medrol is supplied as a sterile suspension for injection for single use.
	Depo-Medrol 40 mg/1 ml Suspension for Injection (40 mg/ml) is available in boxes containing one vial of 1 ml.
	Depo-Medrol 80 mg/2 ml Suspension for Injection (40 mg/ml) is available in boxes containing one 2 ml vial.

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Marketing Authorisation Holder</strong><strong>: </strong></p><p>Pfizer SA, Belgium.</p><p>&nbsp;</p><p><strong>Manufacturer: </strong></p><p>Pfizer Manufacturing Belgium NV, Belgium.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                November 2024
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p dir="RTL">يحتوي هذا الدواء على أسيتات ميثيل بريدنيزولون.</p><p dir="RTL">&nbsp;</p><p dir="RTL">ينتمي أسيتات ميثيل بريدنيزولون إلى مجموعة الأدوية التي يطلق عليها القشرانيات السكرية. يثبط ميثيل بريدنيزولون الأعراض الالتهابية الموضعية (الحرارة، التورم، الألم، الاحمرار) وتفاعلات الحساسية (فرط الحساسية). ويؤثر على العديد من الأعضاء والعمليات الأيضية في الجسم.</p><p dir="RTL">&nbsp;</p><p dir="RTL">ولذلك يستخدم لعلاج العديد من الحالات، مثل:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الاضطرابات الروماتيزمية متنوعة الأسباب؛</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التهاب الوتر؛</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; حالات الحساسية، مثل الربو، الحساسية تجاه الأدوية؛</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الحالات التي تصيب الجلد؛</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; اضطرابات العين الناشئة من حساسية أو التهاب؛</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أنواع معينة من الالتهابات المعدية المعوية؛</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; بعض اضطرابات الجهاز التنفسي؛</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; بعض أمراض الدم الشديدة؛</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الخلل الوظيفي للقشرة الكظرية.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <table dir="rtl" border="1" cellspacing="0" cellpadding="0" align="right" style="width:100%"><tbody><tr><td style="vertical-align:bottom"><p dir="RTL"><strong>موانع استعمال ديبو ميدرول</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت مصابًا بالحساسية تجاه أسيتات ميثيل بريدنيزولون أو أي من المكونات الأخرى التي يحتوي عليها هذا الدواء (المدرجة في القسم ٦)؛</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; في حالة الإصابة بالفُطار (عدوى الجسم بفطر مجهري)؛</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يجب ألا يتم إعطاء ديبو ميدرول عن طريق الوريد، أو داخل القراب، أو فوق الجافية؛</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يجب أيضًا ألا يتم حقن ديبو ميدرول داخل العين أو الأنف، أو في مواضع الحقن الأخرى (فروة الرأس، الحلق، العقدة الوتدية الحنكية).</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الاحتياطات عند استعمال ديبو ميدرول</strong></p><p dir="RTL">تحدث إلى طبيبك أو الصيدلي قبل استخدام ديبو ميدرول:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت مصابًا بداء السكري: قد يزيد ديبو ميدرول من حاجتك إلى الإنسولين أو مضادات السكري الأخرى (التي تخفض من سكر الدم).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعاني من قصور الدرقية، نظرًا لأن ديبو ميدرول سيكون له تأثير أقوى.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعاني فرط نشاط الغدة الدرقية (الغدة الدرقية مفرطة النشاط).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت مصابًا بارتفاع ضغط الدم (ضغط دمك مرتفع للغاية): فقد يزداد الأمر سوءًا.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعاني من اضطرابات انصمامية خثارية (جلطات دموية تسد الأوعية الدموية).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت مصابًا بمرض قلبي: يجب أن تخضع لفحوصات طبية بشكل منتظم.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعاني من قرحة بالمعدة أو من بعض الأمراض الهضمية، مثل التهاب القولون التقرحي (التهاب القولون) أو التهاب الرتج (التهاب الأكياس الصغيرة، الفتوق، في جدار القولون): فقد يتفاقم مرضك. قد يؤدي العلاج بهذا الدواء إلى إخفاء الإصابة بالتهاب الصفاق (التهاب غشاء البطن) أو أعراض أخرى مصاحبة للاضطرابات المعدية المعوية مثل الانثقاب أو الانسداد المعوي أو التهاب البنكرياس.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت قد خضعت مؤخرًا لمفاغرة معوية (نوع من الجراحات المعوية).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت قد أصبت باضطرابات هضمية شديدة.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت قد عانيت بالفعل من مشكلات نفسية مثل التقلب الانفعالي أو إذا كانت لديك ميول ذهانية: فقد تتفاقم هذه المشكلات.</p><p dir="RTL">تحدث إلى طبيبك إذا أصبت بأعراض نفسية خلال العلاج، خاصة إذا كنت مكتئبًا أو كانت تراودك أفكار انتحارية. يمكن أن تحدث اضطرابات نفسية عند تقليل جرعة أو إيقاف هذا النوع من العقار، أو بعد ذلك مباشرة.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعاني من ضعف عضلي شديد (مثل الوهن العضلي الوبيل): فقد يتفاقم مرضك.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت مصابًا بالصرع: يجب أن تخضع لفحوصات طبية بشكل منتظم.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعاني من نقص كالسيوم العظم (هشاشة العظام): فقد يتفاقم مرضك.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا لم تكن وظائف كليتيك تعمل بشكل جيد (القصور الكلوي).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعاني من تصلب الجلد (يعرف أيضًا باسم التصلب الجهازي، وهو مرض مناعي ذاتي بالنسيج الضام)، فقد تم الإبلاغ عن زيادة معدل حدوث النوبات الكلوية الناجمة عن التصلب الجلدي عند استخدام الستيرويدات القشرية.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت مصابًا بالهربس البسيط أو الهربس النطاقي في العين: فهناك خطر لحدوث انثقاب في القرنية مع استخدام هذا الدواء.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعاني أو سبق أن عانيت من السل: يمكن أن يعيد هذا الدواء تنشيط المرض.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعاني أو سبق أن عانيت من حالات عدوى مطولة أو نشطة: فإن هذا الدواء يقلل من دفاعاتك المناعية وقد يؤدي إلى تفاقم مرضك في بعض الحالات. وقد يجعلك أكثر عرضة للإصابة بحالات العدوى مثل الجديري المائي أو الحصبة.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كان العلاج المطول بهذا الدواء ضروريًا، نظرًا لأن الاختبارات المنتظمة ضرورية.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كان حتمًا يحب أن تخضع إلى التطعيم: فلا يوصى بإعطاء لقاحات تحتوي على فيروسات حية أو حية موهنة. قد يكون خطيرًا ومسببًا للعدوى، بناءً على نوع اللقاح، أو قد يكون غير فعال ولن تكون قد اكتسبت أي حماية من المرض المراد التطعيم ضده. قم دائمًا بتنبيه الشخص الذي سيقوم بتطعيمك بأنك تعالَج أو كنت تعالَج باستخدام ديبو ميدرول. اقرأ قسم &quot;الأدوية الأخرى وديبو ميدرول&quot; للحصول على المزيد من المعلومات المفصلة حول اللقاحات.</p><p dir="RTL">&nbsp;</p><p dir="RTL">تواصل مع طبيبك في حالة تغيم الرؤية أو اضطرابات الرؤية الأخرى.</p><p dir="RTL">&nbsp;</p><p dir="RTL">أخبر طبيبك:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت بحاجة إلى الخضوع لاختبار: قد تعطي بعض الاختبارات (مثل قياس مستويات هرمونات الغدة الدرقية) نتائج خاطئة إذا كنت تأخذ ديبو ميدرول.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تحت ضغط غير معتاد: فقد يزيد طبيبك جرعة دوائك خلال هذه الفترة الزمنية العصيبة للحفاظ على فعالية الدواء.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت بحاجة إلى تخدير، يجب إعلام أخصائي التخدير بشأن علاجك بديبو ميدرول.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; بعد حقن ديبو ميدرول، إذا زاد الألم بشكل ملحوظ أو لاحظت تورمًا في موضع الحقن أو قلت مرونة المفاصل أو أصبت بالحمى أو التوعك، فتواصل مع طبيبك على الفور.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أخبر طبيبك قبل العلاج إذا كنت تعاني من ورم في الغدة الكظرية (المعروف أيضًا باسم الفيوكروموسيتوما).</p><p dir="RTL">&nbsp;</p><p dir="RTL">حتى في حال تحسن أعراض المفصل بعد العلاج، تجنب استخدام ذلك المفصل بشكل زائد. قد يؤدي تجاهل هذا التحذير إلى تفاقم إصابات المفصل.</p><p dir="RTL">&nbsp;</p><p dir="RTL">ينبغي اتخاذ التدابير الملائمة لمنع الحقن داخل الأوعية.</p><p dir="RTL">&nbsp;</p><p dir="RTL">ينبغي عدم استخدام الستيرويدات القشرية الجهازية مثل ديبو ميدرول في علاج إصابات الدماغ الرضية.</p><p dir="RTL">&nbsp;</p><p dir="RTL">إذا كنت تتناول بالفعل أدوية أخرى، يُرجى أيضًا قراءة قسم &quot;الأدوية الأخرى وديبو ميدرول&quot;.</p><p dir="RTL">&nbsp;</p><p dir="RTL">يمكن الإصابة بمتلازمة انحلال الورم عند استخدام الستيرويدات القشرية في أثناء علاج السرطان. أخبر طبيبك إذا كنت مصابًا بالسرطان وظهرت عليك أعراض متلازمة انحلال الورم، مثل تشنج العضلات، وضعف العضلات، والارتباك، وضربات القلب غير المنتظمة، وفقدان الرؤية أو اضطرابات الرؤية، وضيق التنفس.</p><p dir="RTL">&nbsp;</p><p dir="RTL">تواصل مع طبيبك على الفور إذا شعرت بضعف في العضلات، وآلام في العضلات، وتشنجات، وتيبس في أثناء استخدام ميثيل بريدنيزولون. فيمكن أن تكون هذه أعراض الإصابة بحالة تُسمى الشلل الانسمامي الدرقي الدوري، قد تحدث لدى المرضى المصابين بالغدة الدرقية مفرطة النشاط (فرط نشاط الغدة الدرقية) الذين يتم علاجهم باستخدام ميثيل بريدنيزولون. قد تحتاج إلى علاج إضافي لتخفيف أعراض هذه الحالة.</p><p dir="RTL">&nbsp;</p><p dir="RTL">أخبر طبيبك في حالة انطباق أي من التحذيرات المذكورة أعلاه عليك، أو إذا كانت قد انطبقت عليك فيما مضى.</p><p dir="RTL"><em>&nbsp;</em></p><p dir="RTL"><strong>الأطفال</strong></p><p dir="RTL">ينبغي أن يراقب الطبيب بعناية نمو وتطور الأطفال حديثي الولادة الذين يتلقون علاجًا مطولًا. من المحتمل حدوث تأخر في النمو خلال العلاج المطول.</p><p dir="RTL">الرضع والأطفال الذين يتم علاجهم لفترة طويلة يكونون عرضة بشكل خاص لخطر الإصابة بارتفاع ضغط الدم داخل القحف.</p><p dir="RTL">يمكن أن تسبب الجرعات العالية من هذا الدواء التهاب البنكرياس لدى الأطفال.</p><p dir="RTL"><em>&nbsp;</em></p><p dir="RTL"><strong>التداخلات الدوائية مع أخذ هذا المستحضر مع أي أدوية أخرى أو أعشاب أو مكملات غذائية</strong></p><p dir="RTL">أخبر طبيبك أو الصيدلي إذا كنت تتناول، أو تناولت مؤخرًا، أو قد تتناول أي دواء آخر إلى جانب ديبو ميدرول، بما في ذلك الأدوية التي يتم الحصول عليها دون وصفة طبية.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مضادات الالتهاب غير الستيرويدية (NSAIDs، مثل إيبوبروفين) والساليسيلات (أدوية تخفيف الألم مثل حمض أسيتيل ساليسيليك):<br />- يؤدي الاستخدام المتزامن لهذه الأدوية مع ديبو ميدرول إلى زيادة خطر الإصابة بقرحة المعدة ونزيف المعدة أو الأمعاء.<br />- يمكن أن يؤدي ديبو ميدرول إلى زيادة إطراح حمض أسيتيل ساليسيليك عن طريق الكليتين. يمكن أن يؤدي توقف العلاج بديبو ميدرول إلى زيادة خطر السمية من الساليسيلات.</p><p dir="RTL">- يمكن أن تؤدي بعض مضادات الالتهاب غير الستيرويدية، مثل فينيل بوتازون، إلى تقليل فعالية ديبو ميدرول.<br />- إذا كنت تعاني من نقص بروثرومبين الدم (انخفاض مستويات عامل تخثر الدم بشكل غير طبيعي)، ينبغي توخي الحذر عند استخدام حمض أسيتيل ساليسيليك خلال العلاج بديبو ميدرول.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مضاد البكتيريا: أيزونيازيد: ينصح بتوخي الحذر عند استخدام هذا الدواء بالتزامن مع ديبو ميدرول.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مضادات التجلط (التي تثبط عملية تخثر الدم): يمكن أن يقل أو يزداد تأثيرها من قِبل ديبو ميدرول.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أدوية علاج السكري (الإنسولين أو مضادات السكري التي تؤخذ عن طريق الفم): قد تحتاج إلى جرعة أكبر من هذه الأدوية للإبقاء على مرض السكري لديك تحت السيطرة، وذلك عند استخدامها بشكل متزامن مع ديبو ميدرول.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مدرات البول (التي تجعلك تنتج المزيد من البول): تزيد من خطر عدم تحمل الجلوكوز عند استخدامها بالتزامن مع ديبو ميدرول وبعض مدرات البول من مجموعة الثيازيد. يمكن أن يؤدي استخدام ديبو ميدرول مع العقاقير الخافضة للبوتاسيوم (مثل مركبات الثيازيد ومدرات البول العروية المشابهة) إلى نقص البوتاسيوم في الدم.</p><p dir="RTL">هناك أيضًا خطر متزايد للإصابة بنقص البوتاسيوم في الدم عند استخدام الستيرويدات القشرية بالتزامن مع الأدوية التالية: أمفوتيريسين ب (يستخدم لبعض حالات العدوى الفطرية)، أو زانثين، أو ناهضات بيتا ٢ (أدوية الربو).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أدوية ارتفاع ضغط الدم (ضغط الدم المرتفع بصورة غير طبيعية): يمكن أن يؤدي استخدام ديبو ميدرول أثناء تناول هذه الأدوية إلى الفقدان التدريجي للسيطرة على ارتفاع ضغط الدم.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يمكن أن تؤدي العقاقير المضادة للصرع (كاربامازيبين، فينوباربيتال، فينيتوين) إلى تقليل فعالية ديبو ميدرول.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الأدوية المضادة للعدوى: المضادات الحيوية الماكروليدية (مثل إريثرومايسين، كلاريثرومايسين، تروليندومايسين) والأدوية المضادة للفطريات (مضادات الفطريات في مجموعة العقاقير التي تتضمن كيتوكونازول وإتراكونازول) يمكن أن تزيد من خطر الجرعة المفرطة من ديبو ميدرول. وعلى العكس، يمكن أن تقلل المضادات الحيوية مثل ريفامبين من فعاليته. وتزيد مضادات كينولون الحيوية من خطر التهاب الأوتار.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; سايكلوسبورين (كابت للمناعة يستخدم بعد عمليات الزرع): هناك خطر متزايد للتعرض للاختلاجات عند استخدامه بشكل متزامن مع ديبو ميدرول. قد تشتد الآثار الجانبية الناتجة عن هذين العقارين عند استخدامهما بشكل متزامن.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الأدوية المستخدمة لعلاج الوهن العضلي الوبيل (الضعف العضلي الشديد): يمكن أن يؤدي الاستخدام المتزامن لديبو ميدرول مع مثبطات الكولينستريز (مثل نيوستجمين وبيريدوستجمين) إلى حدوث أزمة وهن عضلي.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أدوية القلب من مجموعة عقاقير الجليكوسيدات القلبية (على سبيل المثال ديجوكسين): يمكن أن تزداد سميتها عند استعمالها بالتزامن مع ديبو ميدرول.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; العقاقير المضادة للسرطان: يمكن أن يغير ميثوتريكسات من تأثير ديبو ميدرول.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; العقاقير المستخدمة في التخدير: يمكن أن يقلل ديبو ميدرول من تأثير بعض هذه العوامل، خاصة المثبطات العصبية العضلية (مثل بانكورونيوم وفيكورونيوم). لقد لوحظ وجود آثار على العضلات (الاعتلال العضلي الحاد) عند استعمال جرعات عالية من الستيرويدات القشرية بالتزامن مع هذا النوع من العقاقير المضادة للفعل الكوليني.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; محاكيات الودي، مثل سالبوتامول (تستخدم لعلاج الربو وحالات أخرى): يمكن أن يزيد ديبو ميدرول من فعاليتها، لكنه يمكن أن يزيد سميتها المحتملة أيضًا.</p><p dir="RTL">&nbsp;</p><p dir="RTL">قد يَضعُف تأثير ديبو ميدرول أو يزداد عند استخدامه بالتزامن مع أدوية مثل:</p><p dir="RTL">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; بعض الأدوية المستخدمة لعلاج الغثيان والقيء (أبريبيتانت، فوسابريبيتانت)؛</p><p dir="RTL">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ديلتيازيم (يستخدم في حالات الذبحة الصدرية)؛</p><p dir="RTL">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; بعض موانع الحمل التي تؤخذ عن طريق الفم (إيثينيل إستراديول/نوريثيستيرون)؛</p><p dir="RTL">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; بعض الأدوية الكابتة للمناعة (سايكلوفوسفاميد، تاكروليموس)؛</p><p dir="RTL">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; بعض العقاقير المضادة للفيروسات (إندينافير، ريتونافير) ومعززات الحرائك الدوائية (كوبيسيستات) المستخدمة لعلاج فيروس نقص المناعة البشرية (HIV). قد يتغير تأثير هذه الأدوية بسبب الاستعمال المتزامن مع ديبو ميدرول؛</p><p dir="RTL">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أمينوجلوتيثيميد (يستخدم في بعض حالات السرطان).</p><p dir="RTL">&nbsp;</p><p dir="RTL">اللقاحات:</p><p dir="RTL">مبدأ عمل اللقاحات هو تعليم الجهاز المناعي (الآلية الدفاعية في الجسم) التعرّف على الكائن الممرض عن طريق إعطائك جرعات صغيرة جدًا من هذا الكائن. إذا أصبت بعدوى بنفس الكائن الممرض لاحقًا، فسيتعرف جهازك المناعي عليه وسيتخلص منه.</p><p dir="RTL">تبطئ القشرانيات السكرية جهازك المناعي أو حتى تعطّله، فيصبح غير قادر فيما بعد على التعرّف على الكائن الممرض الموجود في اللقاح:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كانت جرعات ديبو ميدرول التي تتلقاها عالية بما يكفي لتعطيل جهازك المناعي، فإن التطعيمات التي تستخدم لقاحات حية أو حية موهنة غير مخصصة للاستعمال. من الممكن حتى أن يتسبب لقاح يحتوي على فيروسات حية موهنة في حدوث عدوى، وهو ما يمكن أن يمثل خطرًا فوريًا إذا لم يتم التحكم فيها بواسطة جهاز مناعي يعمل بصورة طبيعية.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; قد يكون هذا خطيرًا في المستقبل إذا كنت تعتقد أنك محمي لكن اللقاح لم يكن في الواقع فعّالًا؛ لا يوجد خطر للإصابة بعدوى عند استخدام اللقاحات التي لا تحتوي على كائنات ممرضة حية (اللقاحات غير النشطة واللقاحات الحيوية الجينية)، ولكن إذا كان الجهاز المناعي ضعيفًا جدًا فلن يتعلم التعرّف على الكائن الممرض ولذلك سيكون اللقاح غير فعّال.</p><p dir="RTL">إذا كانت جرعة ديبو ميدرول التي تتلقاها منخفضة بما يكفي لعدم تعطيل الجهاز المناعي، يمكن استعمال اللقاحات اللازمة دون وجود أي خطر.</p><p dir="RTL"><em>&nbsp;</em></p><p dir="RTL"><strong>تناول ديبو ميدرول مع الطعام والشراب</strong></p><p dir="RTL">يمكن أن يغير عصير الجريب فروت من تأثيرات ديبو ميدرول.</p><p dir="RTL">&nbsp;</p><p dir="RTL">تحدث دائمًا إلى طبيبك أو الصيدلي بشأن تناول الكحوليات عند استخدام هذا الدواء.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الحمل والرضاعة</strong></p><p dir="RTL">إذا كنتِ حاملًا أو تُرضعين رضاعة طبيعية أو تعتقدين أنكِ ربما تكونين حاملًا أو تخططين للإنجاب، فاستشيري طبيبكِ أو الصيدلي قبل تناول هذا الدواء.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><em>الحمل</em></p><p dir="RTL">لا يوصى بشكل عام باستخدام هذا الدواء أثناء الحمل، إلا إذا تم ذلك بالتشاور مع طبيبكِ. إذا أصبحتِ حاملًا أثناء العلاج بهذا الدواء، فأخبري طبيبكِ.</p><p dir="RTL"><em>&nbsp;</em></p><p dir="RTL"><em>الرضاعة الطبيعية</em></p><p dir="RTL">لا يوصى بشكل عام باستخدام هذا الدواء أثناء الرضاعة الطبيعية، إلا إذا تم ذلك بالتشاور مع طبيبكِ. تمر أدوية الستيرويدات القشرية إلى لبن الثدي.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><em>الخصوبة</em></p><p dir="RTL">لقد أظهرت الدراسات المجراة على الحيوانات أن الستيرويدات القشرية يمكن أن تؤثر على الخصوبة.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>تأثير ديبو ميدرول على القيادة واستخدام الآلات</strong></p><p dir="RTL">تُعد الدوخة، والدوار، واضطرابات الرؤية، والإرهاق آثارًا جانبية محتملة بعد العلاج بالستيرويدات القشرية. اضطرابات الرؤية من الآثار الجانبية النادرة.</p><p dir="RTL">إذا تعرضت لهذه المشكلات، فلا تقم بقيادة المركبات و/أو استخدام الآلات.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>يحتوي ديبو ميدرول على الصوديوم</strong></p><p dir="RTL">يحتوي هذا الدواء على أقل من ۱ مليمول (۲۳ ملجم) من الصوديوم لكل ٤٠ ملجم/١ مل، و٨٠ ملجم/٢ مل، مما يعني أنه &quot;خالٍ من الصوديوم&quot; بشكل أساسي.</p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;</p></td></tr></tbody></table>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <table dir="rtl" border="1" cellspacing="0" cellpadding="0" align="right" style="width:100%"><tbody><tr><td style="vertical-align:bottom"><p dir="RTL">احرص دائمًا على استخدام هذا الدواء تمامًا كما أخبرك طبيبك. راجع طبيبك أو الصيدلي إذا لم تكن متأكدًا مما ينبغي فعله.</p><p dir="RTL">&nbsp;</p><p dir="RTL">الطبيب فقط هو من يمكنه إعطاء هذا الدواء (أو الممرضة في حالة الحقن في العضل). تعتمد الجرعة اللازم إعطاؤها ومدة العلاج على المرض.</p><p dir="RTL">سيحدد طبيبك معدل التكرار والمدة الزمنية التي ينبغي إعطاء هذا الدواء خلالها. اتبع توصيات طبيبك بدقة.</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL">يمكن إعطاء ديبو ميدرول بالطرق التالية:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الحقن في إحدى العضلات (الحقن في العضل)؛</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الحقن داخل أحد المفاصل أو بالقرب منه (الحقن داخل المفصل أو الحقن في محيط المفصل)؛</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الحقن داخل جراب، وهو كيس صغير موجود بين مواضع ارتباط الأوتار (الحقن داخل الجراب)؛</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الحقن داخل إحدى آفات الجلد (الحقن داخل الآفة)؛</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الحقن داخل النسيج الرخو؛</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الحقنة الشرجية (التقطير داخل المستقيم)؛</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الحقن داخل المفصل.</p><p dir="RTL">لا يمكن إعطاء ديبو ميدرول عن طريق أي مسار آخر بخلاف تلك المسارات الموضحة أعلاه.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الجرعة الزائدة</strong><strong> من ديبو ميدرول</strong></p><p dir="RTL">لا تسبب الجرعة المفرطة الحادة من هذا الدواء أي آثار جانبية مرئية فورية. حالات حدوث التسمم الحاد و/أو الوفاة بعد تلقي جرعة مفرطة من الستيرويدات القشرية هي حالات نادرة. في حالة تلقي جرعة مفرطة، لا يوجد ترياق محدد ويتكون العلاج من منح الرعاية الداعمة وتخفيف الأعراض.</p><p dir="RTL">يمكن إزالة ميثيل بريدنيزولون باستخدام الديلزة.</p><p dir="RTL">&nbsp;</p><p dir="RTL">إذا استخدمت أو تلقيت كمية أكبر مما ينبغي من ديبو ميدرول، فاتصل بطبيبك أو الصيدلي أو مركز مكافحة السموم فورًا.</p><p dir="RTL"><em>&nbsp;</em></p><p dir="RTL"><strong>نسيان تناول جرعة ديبو ميدرول</strong></p><p dir="RTL">نظرًا لأنك ستتلقى هذا العلاج تحت إشراف طبي دقيق، فمن غير المرجح أن تُنسى إحدى الحقن. بالرغم من ذلك، إذا كنت تعتقد أن ذلك قد حدث، فأخبر طبيبك. لا تأخذ جرعة مضاعفة لتعويض جرعة منسية. قم بأخذ الجرعة التالية وفقًا للخطة المعتادة.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>التوقف عن تناول ديبو ميدرول</strong></p><p dir="RTL">سيحدد طبيبك المدة الزمنية التي ينبغي عليك استخدام هذا الدواء خلالها. يوصى بالإشراف الطبي عند إيقاف العلاج طويل الأمد، وينبغي إيقاف العلاج تدريجيًا. ينبغي أن ينتبه طبيبك لبدء ظهور أعراض قصور الغدة الكظرية مثل الضعف، والانخفاض في ضغط الدم عند قيامك من وضع الاستلقاء، والاكتئاب.</p><p dir="RTL">قد تحدث &quot;متلازمة انسحاب&quot; مصحوبة بالأعراض التالية إذا تم إنهاء العلاج فجأة: فقدان الشهية الملحوظ، و/أو الغثيان، و/أو القيء، و/أو الخمول، و/أو الصداع، و/أو الحمى، و/أو ألم المفاصل، و/أو انحلال الطبقة السطحية من الجلد، و/أو ألم العضلات، و/أو فقدان الوزن، و/أو ضغط الدم المنخفض.</p><p dir="RTL"><u>&nbsp;</u></p><p dir="RTL">لقد تم الإبلاغ عن حدوث آثار نفسية عقب إيقاف هذا النوع من العقاقير. أخبر طبيبك إذا أصبت بأي اضطرابات نفسية أثناء العلاج أو بعد إيقافه مباشرة.</p><p dir="RTL">&nbsp;</p><p dir="RTL">إذا كانت لديك أي أسئلة إضافية حول استخدام هذا الدواء، فاسأل طبيبك أو الصيدلي.</p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;</p></td></tr></tbody></table>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <table cellspacing="0" cellpadding="0" align="center"><tbody><tr><td style="vertical-align:top"><p dir="RTL">كما هو الحال بالنسبة لجميع الأدوية، يمكن أن يسبب هذا الدواء آثارًا جانبية، غير أنها لا تصيب الجميع.</p><p dir="RTL">&nbsp;</p><p dir="RTL">في حالات نادرة، يمكن أن يسبب هذا الدواء تفاعل حساسية شديدًا من المحتمل أن يكون مميتًا (صدمة تأقية). إذا لاحظت التطور السريع لمشكلات في التنفس، وتورم الوجه والحلق، وشعور عام بالتوعك (الصدمة)، <strong>فاتصل بطبيبك فورًا</strong>.</p><p dir="RTL">&nbsp;</p><p dir="RTL">بشكل عام، يكون خطر الآثار الجانبية منخفضًا إذا استُخدم هذا الدواء لفترة زمنية قصيرة. يزيد هذا الخطر لحدوث الآثار الجانبية عند استعمال جرعات عالية على مدار فترة طويلة.</p><p dir="RTL">&nbsp;</p><p dir="RTL">فيما يلي الآثار الجانبية الرئيسية التي يمكن أن تظهر، بمعدلات حدوث غير معلومة (لا يمكن تقديرها من خلال البيانات المتاحة):</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <em>الاضطرابات القلبية: </em>فشل القلب الاحتقاني (لدى المرضى المعرّضين للإصابة به).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <em>الاضطرابات الوعائية:</em> ضغط الدم المرتفع (ارتفاع ضغط الدم) أو ضغط الدم المنخفض (انخفاض ضغط الدم)، زيادة تجلط الدم، أو سخونة الجلد واحمراره (الاحمرار).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <em>اضطرابات الدم:</em> زيادة عدد خلايا الدم البيضاء.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <em>اضطرابات العضلات والعظام:</em> ضعف العضلات، أو فقدان الكالسيوم في العظام (هشاشة العظام)، أو تأخر النمو، أو الكسور، أو انضغاط النخاع نتيجة الكسر، أو فقدان كتلة العضلات، أو تمزق الأوتار خاصة وتر أخيل (بين ربلة الساق والقدم)، أو تحلل العظام، أو اضطرابات المفاصل، أو مرض العضلات (الاعتلال العضلي)، أو ألم العضلات، أو ألم المفاصل، أو نوبة احتدام للألم بعد الحقن (زيادة مؤقتة في الشعور بالألم في موضع الحقن).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <em>الاضطرابات المعدية المعوية:</em> القرحة الهضمية مع خطر حدوث انثقاب ونزف، نزيف في المعدة، الانثقاب المعوي، التهاب البنكرياس، التهاب المريء (المصحوب أو غير المصحوب بقرحة)، ألم البطن، الانتفاخ، الإسهال، الاضطرابات الهضمية، الغثيان، القيء.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <em>الاضطرابات</em> الكبدية والصفراوية: قد يسبب ميثيل بريدنيزولون تلفًا لكبدك. لقد تم الإبلاغ عن حالات إصابة بالتهاب الكبد الوبائي وزيادة في إنزيمات الكبد.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <em>اضطرابات الجلد:</em> الورم الوعائي (تفاعل حساسية)، التكدم، حب الشباب، وجود بقع حمراء صغيرة تحت الجلد نتيجة تسرّب الدم إلى الجلد (الحبرات)، علامات تمدد الجلد، زيادة تلون الجلد الطبيعي (فرط التصبغ) أو انخفاض تلون الجلد الطبيعي (نقص التصبغ)، فرط نمو الشعر لدى السيدات (غزارة في نمو الشعر)، تغير الجلد في موضع الحقن (ضمور في الجلد وتحت الجلد قد يسبب حالات تنقر بالجلد)، الطفح الجلدي، احمرار الجلد، الحكة، الشرى، فرط العرق.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <em>اضطرابات الأيض والتغذية:</em> خلل في القدرة على تحمل الجلوكوز، زيادة الحاجة إلى الإنسولين أو الدواء لخفض مستويات سكر الدم لدى الأشخاص المصابين بداء السكري، تراكم الصوديوم، احتباس السوائل، فقدان البوتاسيوم (وهو ما يمكن أن يؤدي إلى زيادة قلوية الدم بسبب نقص بوتاسيوم الدم)، وجود تغيرات في مستويات الدهون في الدم (عسر شحميات الدم)، زيادة الشهية (وهو ما يمكن أن يؤدي إلى زيادة الوزن)، تراكم الأنسجة الدهنية في أجزاء مختلفة من الجسم، ارتفاع نسبة حموضة الدم (الحماض الأيضي).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <em>اضطرابات الأذن وتجويف الأذن:</em> الدوار.</p><p dir="RTL"><em>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </em><em>اضطرابات الجهاز العصبي</em>: زيادة الضغط داخل القحف، النوبات، فقدان الذاكرة، اضطرابات الوظائف<em> الإدراكية، الدوار، الصداع. </em></p><p dir="RTL"><em>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </em><em>اضطرابات الصحة العقلية: الاضطرابات العاطفية (بما في ذلك الاكتئاب، النشوة، عدم الاستقرار العاطفي، الاعتماد</em> النفسي، الأفكار الانتحارية). الاضطرابات العقلية الشديدة (بما في ذلك الانتشاء، والأوهام، والهلاوس، و[تفاقم] الفصام)، الارتباك، الاضطرابات العقلية، القلق، تغيرات في الشخصية، التقلبات المزاجية، السلوكيات غير الطبيعية.<br />تحدث الأعراض التالية بشكل أكثر شيوعًا لدى الأطفال: التقلبات المزاجية، السلوكيات غير الطبيعية، الأرق، الشعور بالتهيج.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <em>الاضطرابات الهرمونية:</em> السمنة في الجزء العلوي من الجسم مع مظهر يتسم بانتفاخ الوجه واحمراره وهو ما يُسمى بوجه القمر (متلازمة كوشينج)، قصور في إفراز هرمونات الغدة النخامية (تثبيط المحور الوطائي النخامي الكظري)، عدم انتظام دورات الحيض، متلازمة انسحاب الستيرويدات (انظر القسم ٣، &quot;إذا توقفت عن استخدام ديبو ميدرول&quot;).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <em>اضطرابات العين:</em> إعتام عدسة العين، الزرق، بروز العينين (جحوظ العينين)، حالات نادرة من فقدان البصر في حالة الحقن داخل آفة في منطقة الوجه أو الرأس، أمراض الشبكية وغشاء المشيمية، تغيم الرؤية.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <em>اضطرابات</em> الجهاز المناعي: تفاعلات الحساسية، وتفاعلات حساسية خطيرة يحتمل أن تكون مميتة (بما في ذلك زيادة الحساسية تجاه المواد الغريبة).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <em>حالات العدوى</em>: حالات العدوى، العدوى الانتهازية (الناتجة عن كائنات ممرضة تكون عادة غير ضارة لأن الجهاز المناعي يبقيها تحت السيطرة، لكنها قد تصبح خطيرة إذا لم يعد يبقيها الجهاز المناعي تحت السيطرة)، حالات العدوى في موضع الحقن، التهاب بطانة تجويف البطن (التهاب الصفاق).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <em>الاضطرابات التنفسية:</em> انسداد أحد الأوعية الدموية في الرئتين (الانصمام الرئوي)، الزغطة المستمرة.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <em>الحالات العامة واضطرابات موضع الاستعمال:</em> تأخر الالتئام، التورم (التورم المحيطي)، تفاعل في موضع الحقن، الخراج المعقم (دون وجود كائنات ممرضة)، الإرهاق، التوعك.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <em>الاختبارات والفحوصات:</em> انخفاض البوتاسيوم، تغير في نتائج فحص الدم الخاص بوظائف الكبد (الفوسفاتاز القلوي)، ارتفاع ضغط العين، قلة تحمل الكربوهيدرات، زيادة الكالسيوم في البول، تثبيط التفاعلات تجاه اختبارات الجلد، زيادة اليوريا في الدم.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الإبلاغ عن الأعراض الجانبية</strong></p><p dir="RTL">إذا أصبت بأي آثار جانبية، فتحدث إلى طبيبك أو الصيدلي. يتضمن هذا أي آثار جانبية محتملة غير مدرجة في هذه النشرة. يمكنك أيضًا الإبلاغ عن الآثار الجانبية مباشرةً عبر نظام الإبلاغ القومي بالإبلاغ عن الآثار الجانبية، يمكنك المساعدة في توفير المزيد من المعلومات حول سلامة هذا الدواء.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>للإبلاغ عن الأعراض الجانبية</strong></p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong><em>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </em></strong><strong>المملكة العربية السعودية:</strong></p><p dir="RTL"><em>&nbsp;</em></p><table dir="rtl" border="0" cellspacing="0" cellpadding="0" style="width:100%"><tbody><tr><td style="vertical-align:top"><p dir="RTL">المركز الوطني للتيقظ الدوائي:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مركز الاتصال الموحد: ١٩٩٩٩</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; البريد الالكتروني: npc.drug@sfda.gov.sa</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الموقع الالكتروني: https://ade.sfda.gov.sa</p></td></tr></tbody></table><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong><strong>دول </strong><strong>الخليج</strong><strong> الأخرى:</strong></p><p dir="RTL">&nbsp;</p><table dir="rtl" border="1" cellspacing="0" cellpadding="0" style="width:100%"><tbody><tr><td style="vertical-align:top"><p dir="RTL"><em>-&nbsp; الرجاء الاتصال بالمؤسسات والهيئات الوطنية في كل دولة.</em></p></td></tr></tbody></table></td></tr></tbody></table>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">احتفظ بهذا الدواء بعيدًا عن مرأى ومتناول الأطفال.</p><p dir="RTL">يحفظ في درجة حرارة أقل من ٣٠ درجة مئوية.</p><p dir="RTL">&nbsp;</p><p dir="RTL">لا تستخدم هذا الدواء بعد تاريخ انتهاء الصلاحية المدون على العبوة الكرتونية بعد الرمز &quot;<strong>EXP</strong>&quot;. يشير تاريخ انتهاء الصلاحية إلى آخر يوم من الشهر المذكور.</p><p dir="RTL">&nbsp;</p><p dir="RTL">صلاحية المستحضر ٣٦ شهر.<br />&nbsp;</p><p dir="RTL">لا تتخلص من أي أدوية عبر مياه الصرف أو مع المخلفات المنزلية. اسأل الصيدلي عن كيفية التخلص من الأدوية التي لم تعد تستخدمها. ستساعد هذه التدابير على حماية البيئة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; المادة الفعالة في هذا الدواء هي أسيتات ميثيل بريدنيزولون.</p><p dir="RTL">-&nbsp;&nbsp; يحتوي ديبو ميدرول ٤٠ ملجم/١ مل على ٤٠ ملجم من أسيتات ميثيل بريدنيزولون في ١ مل معلق للحقن (٤٠ ملجم/مل).</p><p dir="RTL">-&nbsp;&nbsp; يحتوي ديبو ميدرول ٨٠ ملجم/٢ مل على ٨٠ ملجم من أسيتات ميثيل بريدنيزولون في ٢ مل معلق للحقن (٤٠ ملجم/مل).</p><p dir="RTL">-&nbsp;&nbsp; &nbsp;<strong>&nbsp;</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; المكونات الأخرى في هذا الدواء هي</p><p dir="RTL">ماكروجول ٣٣٥٠؛ ميريستيل- جاما- كلوريد البيكولينيوم؛ كلوريد الصوديوم؛ ماء للحقن &nbsp;</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">يتم تزويد ديبو ميدرول في صورة معلق معقم للحقن للاستخدام مرة واحدة فقط.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يتوفر معلق ديبو ميدرول ٤٠ ملجم/١ مل للحقن (٤٠ ملجم/مل) في عبوات تحتوي على زجاجة واحدة سعة ١ مل.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يتوفر معلق ديبو ميدرول ٨٠ ملجم/٢ مل للحقن (٤٠ ملجم/مل) في عبوات تحتوي على زجاجة واحدة سعة ٢ مل.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <table cellspacing="0" cellpadding="0" align="center"><tbody><tr><td style="vertical-align:top"><p dir="RTL"><em>&nbsp;</em></p><p dir="RTL"><strong>الشركة المسوقة</strong><strong>: </strong></p><p dir="RTL">Pfizer SA, Belgium</p><p dir="RTL"><em>&nbsp;</em></p><p dir="RTL"><strong>الشركة الصانعة: </strong></p><p dir="RTL">Pfizer Manufacturing Belgium NV, Belgium</p></td></tr></tbody></table>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            نوفمبر/تشرين الثاني ٢٠٢٤.
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Depo-Medrol 40 mg/1 mL suspension for injection
Depo-Medrol 80 mg/2 mL suspension for injection

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                The active substance is methylprednisolone. 

Depo-Medrol 40 mg/1 mL contains 40 mg methylprednisolone acetate in 1 mL of suspension for injection (40 mg/mL).
Depo-Medrol 80 mg/2 mL contains 80 mg methylprednisolone acetate in 2 mL of suspension for injection (40 mg/mL).

For the full list of excipients, see section 6.1.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Sterile suspension for injection, for single use.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Glucocorticoids should be considered as a purely symptomatic treatment, except in some endocrine disorders, in which they are administered as replacement therapy.</p><p>&nbsp;</p><p>A. Intramuscular administration</p><p><br />Methylprednisolone acetate (Depo-Medrol) is not suitable for the treatment of acute life-threatening conditions. If a rapid hormonal effect of maximum intensity is required, a highly soluble glucocorticoid agent such as methylprednisolone sodium succinate (Solu-Medrol) should be administered intravenously.</p><p>&nbsp;&nbsp;&nbsp;&nbsp; When oral administration is not feasible and this medicinal product is suitable for the treatment of the condition, the intramuscular use of Depo-Medrol is indicated in the following cases:</p><p>&nbsp;</p><p><u>Anti-inflammatory treatment</u></p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <u>Rheumatic disorders </u><br />As an adjuvant to maintenance treatment (analgesics, kinesiotherapy, physiotherapy, etc.) and for short-term administration (to tide the patient over an acute episode or exacerbation) in:</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Psoriatic arthritis</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Ankylosing spondylitis</p><p>For the following indications, in situ administration of the medicinal product is preferable wherever possible:</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Post-traumatic osteoarthritis</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Synovitis at site of osteoarthritis</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Rheumatoid arthritis, including the juvenile form (in some cases, low-dose maintenance treatment may be necessary)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Acute or subacute bursitis</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Epicondylitis</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Acute nonspecific tenosynovitis</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Acute gouty arthritis</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <u>Collagen diseases</u><br />During an exacerbation or as maintenance treatment in selected cases of:</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Systemic lupus erythematosus</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Systemic dermatomyositis (polymyositis)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Acute rheumatic heart disease</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Skin disorders</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Pemphigus</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Severe erythema multiforme (Stevens-Johnson syndrome)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Exfoliative dermatitis</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Mycosis fungoides</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Bullous dermatitis herpetiformis (sulfones are the treatment of first choice, with systemic administration of glucocorticoids as adjunctive treatment)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <u>Allergic disorders</u><br />Control of severe or incapacitating allergic conditions unresponsive to appropriate conventional treatment, in cases of:</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Chronic asthmatic respiratory disorders</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Contact dermatitis</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Atopic dermatitis</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Serum sickness</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Medicinal product allergy</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Post-transfusion urticaria</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Quincke&#39;s oedema (adrenaline is the medicinal product of first choice)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <u>Eye disorders</u><br />Severe acute and chronic allergic and inflammatory processes involving the eye, such as:</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Herpes zoster ophthalmicus</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Iritis, iridocyclitis</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Chorioretinitis</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Diffuse posterior uveitis</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Optic neuritis</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <u>Gastrointestinal disorders</u><br />To tide the patient over a critical period in cases of:</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Ulcerative colitis (systemic treatment)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Crohn&#39;s disease (systemic treatment)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <u>Oedema conditions</u></p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; To induce diuresis or remission of proteinuria in cases of nephrotic syndrome without uraemia, of the idiopathic type or due to lupus erythematosus</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <u>Respiratory disorders</u></p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Symptomatic pulmonary sarcoidosis</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Berylliosis</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Fulminant or disseminated pulmonary tuberculosis, in combination with concomitant administration of appropriate anti-tuberculosis medicinal products</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Loeffler syndrome, unresponsive to conventional treatment</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Aspiration pneumonia</p><p>&nbsp;</p><p><u>Treatment of haematology and oncology disorders </u></p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Haematological disorders</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Acquired (autoimmune) haemolytic anaemia</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Secondary thrombocytopenia in adults</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Erythroblastopenia (aplastic anaemia)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Congenital (erythroid) hypoplastic anaemia</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <u>Oncology disorders </u></p><p>For the palliative treatment of:</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Leukaemia and lymphoma in adults</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Acute leukaemia in children</p><p>&nbsp;</p><p><u>Endocrine disorders</u></p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Primary or secondary adrenocortical insufficiency</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Acute adrenocortical insufficiency</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; (For these indications, hydrocortisone or cortisone are the medicinal products of choice. In some cases, synthetic analogues may be used provided they are combined with a mineralocorticoid. In children, a mineralocorticoid supplement is particularly important.)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Congenital adrenal hyperplasia</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Hypercalcaemia associated with cancer</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Non-purulent thyroiditis</p><p>&nbsp;</p><p><u>Miscellaneous</u></p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Suspected or existing tuberculous meningitis with subarachnoid block, in combination with suitable tuberculostatics</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Trichinosis with neurological or myocardial involvement</p><p>&nbsp;</p><p>B. Intrasynovial, periarticular, intrabursal or soft tissue administration (see also section 4.4)</p><p>&nbsp;</p><p>&nbsp;&nbsp;&nbsp;&nbsp; Depo-Medrol is indicated as an adjuvant in short-term use (to tide the patient over an acute episode or exacerbation) in cases of:</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Synovitis at site of osteoarthritis</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Rheumatoid arthritis</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Acute or subacute bursitis</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Acute gouty arthritis</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Epicondylitis</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Acute nonspecific tenosynovitis</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Post-traumatic osteoarthritis</p><p>&nbsp;</p><p>C. In intralesional administration</p><p><br />Intralesional administration of Depo-Medrol is indicated in the following disorders:</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Keloids</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Localised hypertrophic, infiltrated, inflammatory lesions of: lichen planus, plaque psoriasis, granuloma annulare and lichen simplex chronicus (circumscribed neurodermatitis)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Discoid lupus erythematosus</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Alopecia areata</p><p>Infiltration of Depo-Medrol may also be useful in cystic tumours, aponeurosis or tendinitis (ganglia).</p><p>&nbsp;</p><p>D. Intrarectal instillation</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Ulcerative colitis</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Posology</u></p><p>&nbsp;</p><p>A. Administration for systemic effect</p><p><br />Intramuscular dosage varies based on the severity of the condition being treated. If a prolonged effect is desired, the weekly dose is calculated by multiplying the daily oral dose by 7 and should be administered as a single intramuscular injection.</p><p><br />Dosage must be adjusted individually according to the severity of the disease and response of the patient. As a general rule, the treatment should be as short as possible. Medical supervision is required.</p><p>&nbsp;</p><p>Hormone therapy is an adjunct to and not a replacement for conventional treatment. Dosage must be decreased or treatment must be discontinued gradually when the medicinal product has been administered for more than a few days. Close medical supervision is recommended when chronic treatment is discontinued.<br />The severity and expected duration of the disorder and patient response to the medicinal product are primary factors in determining dosage. In cases of spontaneous remission of a chronic disorder, treatment should be discontinued. In chronic treatment, regular laboratory examinations should include urine analysis, blood sugar two hours after eating, blood pressure, body weight and chest X-ray. In patients having suffered from a gastric ulcer or severe dyspepsia, an X-ray of the upper gastrointestinal tract is recommended.</p><p><br />In patients with adrenogenital syndrome, a single intramuscular injection of 40 mg every two weeks may be indicated. For maintenance of patients with rheumatoid arthritis, weekly intramuscular dosage varies from 40 to 120 mg. The usual dosage for patients with skin lesions relieved by systemic corticosteroid therapy is 40 to 120 mg of methylprednisolone acetate administered intramuscularly for one to four weeks. In acute severe dermatitis due to poison ivy, relief may result within 8 to 12 hours following intramuscular administration of a single dose of 80 to 120 mg. In chronic contact dermatitis, it may be necessary to repeat the injection after 5 to 10 days. In seborrheic dermatitis, a weekly dose of 80 mg may be adequate to mitigate symptoms.<br />Following intramuscular administration of 80 to 120 mg to asthmatic patients, relief may result within 6 to 48 hours and may persist for several days to two weeks.</p><p>&nbsp;</p><p>If the disorder is combined with signs of stress, dosage should be increased. If a rapid hormonal effect of maximum intensity is required, the intravenous administration of highly soluble methylprednisolone sodium succinate is indicated.</p><p>&nbsp;</p><p>B. In situ administration for local effect</p><p><br />Treatment with Depo-Medrol does not obviate the need for the conventional measures usually employed. Although this method of treatment relieves symptoms, in no way is it a cure; the hormone has no effect on the cause of the inflammation.<br />&nbsp;</p><p>&nbsp;&nbsp;&nbsp;&nbsp; <u>Procedure</u></p><p>1.&nbsp;&nbsp; <u>Rheumatoid and osteoarthritis</u><br />The dose for intra-articular administration depends upon the size of the joint and varies with the severity of the condition in the individual patient. In chronic cases, injections may be repeated at intervals ranging from one to five or more weeks, depending upon the degree of relief obtained from the initial injection. The following table is provided for information purposes:</p><p>&nbsp;</p><table border="0" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>Size of joint</p></td><td style="vertical-align:top"><p>Examples</p></td><td style="vertical-align:top"><p>Dosage</p></td></tr><tr><td style="vertical-align:top"><p>Large</p></td><td style="vertical-align:top"><p>Knee</p></td><td style="vertical-align:top"><p>20 to 80&nbsp;mg</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Ankle</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Shoulder</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Average</p></td><td style="vertical-align:top"><p>Elbow</p></td><td style="vertical-align:top"><p>10 to 40&nbsp;mg</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Wrist</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Small</p></td><td style="vertical-align:top"><p>Metacarpophalangeal</p></td><td style="vertical-align:top"><p>4 to 10&nbsp;mg</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Interphalangeal</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Sternoclavicular</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Acromioclavicular</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr></tbody></table><p>&nbsp;</p><p>It is recommended that the anatomy of the joint be extensively reviewed before attempting intra-articular injection. In order to obtain an optimal anti-inflammatory effect, it is important that the injection be made into the synovial space. Using the same sterile technique as for a lumbar puncture, a sterile 20- to 24-gauge needle (on a dry syringe) is quickly inserted into the synovial cavity. Procaine infiltration is elective. The aspiration of only a few drops of joint fluid proves the joint space has been entered by the needle. The injection site for each joint is determined by the location where the synovial cavity is most superficial and most free of large vessels and nerves. With the needle in place, the aspirating syringe is removed and replaced by a second syringe containing the desired amount of Depo-Medrol. A small quantity of synovial fluid is aspirated to make sure the needle is still in the synovial space. After injection, the joint is moved gently a few times to aid mixing of the synovial fluid and the suspension. The injection site is then covered with a small sterile dressing.</p><p><br />Suitable sites for intra-articular injection are the knee, ankle, wrist, elbow, shoulder, phalangeal and hip joints. It is often difficult to enter the hip joint; precautions should be taken to avoid any large blood vessels in the area. Joints not suitable for injection are those that are anatomically inaccessible, such as the spinal and sacroiliac joints, which are devoid of synovial cavity. Treatment failures are most frequently the result of penetration outside the synovial cavity. An injection into the surrounding tissue usually results in little or no benefit. If failures occur when injections into the synovial space are certain (as determined by aspiration of fluid), repeated injections are usually futile. Local treatment does not alter the underlying disease process and should whenever possible be complemented with physiotherapy and orthopaedic correction.</p><p>&nbsp;</p><p>2.&nbsp;&nbsp; <u>Bursitis</u><br />The area around the injection site should be cleaned carefully and an infiltration at the site made with 1% procaine hydrochloride solution. A 20- to 24-gauge needle attached to a dry syringe is inserted into the bursa and the fluid aspirated. The needle is left in place and the aspirating syringe replaced with a small syringe containing the desired dose. After injection, the needle is withdrawn and a small dressing applied.</p><p>&nbsp;</p><p>3.&nbsp;&nbsp; <u>Miscellaneous: ganglia, tendinitis, epicondylitis</u><br />&nbsp;In the treatment of conditions such as tendinitis or tenosynovitis, care should be taken to inject the suspension into the tendon sheath rather than into the substance of the tendon. The tendon may be readily palpated when stretched. When treating epicondylitis, the most painful area should be outlined carefully and the suspension infiltrated into that area. For ganglia of the tendon sheaths, the suspension should be injected directly into the cyst. In many cases, a single injection results in a marked decrease in the size of the cyst or even its disappearance.<br />According to the severity of the disorder, dosage may range from 4 to 30 mg. In recurrent or chronic disorders, repeated injections may prove necessary.</p><p>&nbsp;</p><p>The usual sterile precautions should be observed for each injection (application of a suitable antiseptic to the skin).</p><p>&nbsp;</p><p>4.&nbsp;&nbsp; <u>Injections for local effect in skin conditions</u><br />Following extensive cleansing with an appropriate antiseptic such as 70% alcohol, 20 to 60 mg is injected into the lesion. In cases of large lesions, it may be necessary to distribute doses of 20 to 40 mg over repeated local injections. Care should be taken to avoid injection of quantities likely to cause discolouration, as this may result in a small necrosis. One to four injections are usually given. The intervals between injections vary with the type of lesion and the duration of improvement produced by the initial injection.</p><p>&nbsp;</p><p>C. Intrarectal administration</p><p><br />Depo-Medrol in doses of 40 to 120 mg administered as retention enemas or by continuous drip three to seven times weekly for periods of two or more weeks, have been shown to be a useful adjunct in the treatment of some patients with ulcerative colitis. The condition of many patients can be controlled with 40 mg of Depo-Medrol administered in 30 to 300 mL of water. Naturally, other accepted therapeutic measures should be instituted.</p><p>&nbsp;</p><p><em>Paediatric population</em></p><p>&nbsp;</p><p>Although a lower dose should be administered to children and infants, this dose should nevertheless be determined on the basis of the severity of the disorder rather than on age and body weight.</p><p><em>&nbsp;</em></p><p><u>Method of administration</u></p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Intramuscular</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Intra-articular, periarticular, intrabursal or soft tissues</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Intralesional</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Intrarectal instillation</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Intrasynovial</p><p>&nbsp;</p><p>Depo-Medrol should not be administered by any route other than listed in section 4.1 (see also section &ldquo;Adverse reactions reported with contraindicated routes of administration&rdquo; in section 4.8, &ldquo;Undesirable effects&rdquo;).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                -	Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.
-	Intrathecal administration
-	Intravenous administration
-	Epidural administration
-	Intranasal or ophthalmic administration, or administration at various injection sites (scalp, oropharynx, sphenopalatine ganglion)
-	Systemic mycoses

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>This product should not be used for more than one dose. After administration of the desired dose, the remaining suspension should be discarded (see section 6.6).</p><p>&nbsp;</p><p>In order to minimise the incidence of dermal and subdermal atrophy, care must be exercised not to exceed the recommended doses. If possible, multiple small injections should be made in the region of the lesion. The techniques of intra-articular and intramuscular injection should also include precautions against dermal injection or infiltration. Injection into the deltoid muscle should be avoided due to a significant incidence of subcutaneous atrophy.</p><p>&nbsp;</p><p>Severe adverse reactions have been reported in association with the following contraindicated routes of administration: intrathecal/epidural, intranasal, ophthalmic and administration at various injection sites (see section 4.8). Appropriate measures must be taken to avoid intravascular injection.</p><p>&nbsp;</p><p><strong>Intra-articular use</strong></p><p>In cases of intra-articular use and/or other local administration, a strict sterile technique is needed to avoid iatrogenic infections.</p><p>Following intra-articular corticosteroid administration, care should be taken to avoid overuse of joints in which symptomatic benefit has been obtained. If this instruction is not respected, the therapeutic effect of the steroids may not only be entirely negated, the joint damage may actually be aggravated. Injections into unstable joints are not recommended. In some cases, repeated intra-articular injection may cause joint instability. Any deterioration may be identifiable by X-ray. When a local anaesthetic is administered before injection of Depo-Medrol, the instructions for use of the anaesthetic must be read carefully, and all necessary precautions must be taken.</p><p>&nbsp;</p><p><strong>The following additional precautions apply to glucocorticoids administered parenterally</strong></p><p>Intrasynovial injection of corticosteroids may result in both systemic and local effects.</p><p>To exclude the possibility of infection, an appropriate examination of the synovial fluid is required.</p><p>A marked increase in pain accompanied by local swelling, reduction in joint motion, fever and malaise are potential symptoms of suppurative acute arthritis. If this complication occurs and the diagnosis of sepsis is confirmed, treatment with local injections of glucocorticoids must be discontinued, and appropriate antimicrobial therapy started.</p><p>Local injection of steroids should be avoided in cases of pre-existing joint infections.</p><p>Glucocorticoids must not be injected into unstable joints. Sterile technique is absolutely necessary to avoid infections and contamination.</p><p>&nbsp;</p><p><strong>Immunosuppressive effects/Increased susceptibility to infection</strong></p><p>Corticosteroids may increase susceptibility to infection, may mask some signs of infection and new infections may appear during their use. Corticosteroid use may result in decreased resistance and inability to locate the infection. Infections with any pathogen including viral, bacterial, fungal, protozoan or helminthic organisms, in any location in the body, may be associated with the use of corticosteroids alone or in combination with other immunosuppressive agents that affect cellular immunity, humoral immunity or neutrophil action. These infections may be moderate, severe and occasionally fatal. The higher the dose of corticosteroids, the higher the incidence of infectious complications.</p><p>Do not use intra-articularly, intrabursally or intratendinously for local effect in cases of acute infection. Intramuscular administration should only be considered after an appropriate antimicrobial treatment is started.</p><p>&nbsp;</p><p>Patients taking medicinal products that suppress the immune system are more susceptible to infections than healthy individuals. For example, chickenpox and measles may have a more serious or even fatal course in non-immune children or adults taking corticosteroids.</p><p>&nbsp;</p><p>The administration of live or attenuated live vaccines is not recommended in patients receiving immunosuppressive doses of corticosteroids. Inactivated and biogenetic vaccines may however be administered in these patients. The therapeutic response to these vaccines may nonetheless be reduced, and the vaccines may even be ineffective. In patients receiving non-immunosuppressive doses of corticosteroids, the necessary vaccinations can be administered as usual.</p><p>&nbsp;</p><p>The use of Depo-Medrol in active tuberculosis should be limited to cases of fulminating or disseminated tuberculosis in which the corticosteroid is associated with an adequate tuberculosis treatment. Close monitoring of patients with latent tuberculosis or presenting a positive tuberculin test is required, as corticosteroids may result in the reactivation of the disease. During prolonged corticosteroid therapy, these patients should receive chemoprophylactic treatment.</p><p>&nbsp;</p><p>Kaposi&#39;s sarcoma has been reported in patients treated with corticosteroids. Discontinuation of corticosteroids may result in clinical remission.</p><p>&nbsp;</p><p>The role of corticosteroids in septic shock has been controversial, with early studies reporting both beneficial and detrimental effects. More recently, supplemental corticosteroids have been suggested to be beneficial in patients with established septic shock who exhibit adrenal insufficiency. However, their routine use in septic shock is not recommended.<sup> </sup>A systematic review of short-term treatment with high-dose corticosteroids did not support their use. However, meta-analyses and a review suggest that longer courses (5-11 days) of low-dose corticosteroids might reduce mortality, especially in patients with septic shock requiring vasopressor treatment.</p><p><strong>&nbsp;</strong></p><p><strong>Effects on the immune system</strong></p><p>Allergic reactions may occur. Rare cases of anaphylactic reactions in patients treated with parenteral glucocorticoids have been reported. For this reason, appropriate precautions should be taken prior to administration, especially when the patient has a history of allergy to these medicinal products.</p><p>&nbsp;</p><p><strong>Endocrine effects</strong></p><p>In patients treated with corticosteroids who are subject to an unusually stressful event, an increase in the dose of rapid-action corticosteroids is indicated before, during and after the stressful event.</p><p>Pharmacologic doses of corticosteroids administered for prolonged periods may result in hypothalamic-pituitary-adrenal (HPA) suppression (secondary adrenocortical insufficiency). The degree and duration of adrenocortical insufficiency produced is variable among patients and depends on the dose, frequency, time of administration, and duration of corticosteroid therapy. This effect may be minimised by administering the treatment every other day.</p><p>In addition, acute adrenal insufficiency leading to a fatal outcome may occur if glucocorticoids are withdrawn abruptly. Secondary medicinal product-induced adrenocortical insufficiency may therefore be minimised by gradual reduction of dosage. This type of relative insufficiency may persist for months after discontinuation of therapy. Hormone therapy should therefore be restarted in any situation of stress occurring during that period.</p><p>A steroid &ldquo;withdrawal syndrome&rdquo;, seemingly unrelated to adrenocortical insufficiency, may also occur following abrupt discontinuation of glucocorticoids. This syndrome includes symptoms such as: anorexia, nausea, vomiting, lethargy, headache, fever, joint pain, peeling of the skin, myalgia, weight loss, and/or hypotension. These effects are thought to be due to the sudden change in glucocorticoid concentration rather than to low corticosteroid levels.</p><p>&nbsp;</p><p>As glucocorticoids may result in or aggravate Cushing&#39;s syndrome, they should be avoided in patients with Cushing&rsquo;s disease.</p><p>&nbsp;</p><p>The effects of corticosteroids increase in patients with hypothyroidism.</p><p>&nbsp;</p><p><strong>Metabolism and nutrition</strong></p><p>Corticosteroids, including methylprednisolone, may increase blood glucose, worsen pre-existing diabetes and predispose patients taking long-term corticosteroid therapy to diabetes mellitus.</p><p>&nbsp;</p><p><strong>Psychiatric effects</strong></p><p>During corticosteroid therapy, psychic disorders may occur, from euphoria, insomnia, mood swings, personality disorders and severe depression to evident psychotic disorders. Similarly, existing emotional instability or psychotic tendencies may be aggravated by corticosteroids.</p><p>&nbsp;</p><p>Potentially severe psychiatric adverse reactions may occur with systemic steroids. These symptoms typically emerge within a few days or weeks of starting treatment. Most of these reactions disappear after dose reduction or withdrawal, although specific treatment may be necessary. Psychological effects have been reported upon withdrawal of corticosteroids; their frequency is unknown. Patients/caregivers should be encouraged to seek medical attention if psychological symptoms develop in the patient, especially if depressed mood or suicidal ideation is suspected. Patients/caregivers should be alert to possible psychiatric disturbances that may occur either during or immediately after dose reduction/withdrawal of systemic steroids.</p><p>&nbsp;</p><p><strong>Nervous system effects</strong></p><p>Corticosteroids should be used with caution in patients with epileptic disorders.</p><p>&nbsp;</p><p>Corticosteroids should be used with caution in patients with myasthenia gravis (see also the paragraph on myopathy in section 4.4,&nbsp;Musculoskeletal effects).</p><p>&nbsp;</p><p>Cases of epidural lipomatosis have been reported in patients treated with corticosteroids, usually when used at high doses in the long term.</p><p><strong>&nbsp;</strong></p><p><strong>Ocular effects</strong></p><p>Prolonged use of corticosteroids may cause posterior subcapsular and nuclear cataracts (particularly in children), exophthalmos, or increased intraocular pressure, which may result in glaucoma with possible damage to the optic nerves, and may promote the development of secondary ocular infections due to fungi or viruses.</p><p>Given the risk of corneal perforation, glucocorticoids should be administered with caution in patients with ocular herpes simplex or herpes zoster with ophthalmic symptoms.</p><p>Visual disturbance may be reported with systemic and topical corticosteroid use. If a patient presents with symptoms such as blurred vision or other visual disturbances, the patient should be considered for referral to an ophthalmologist for evaluation of possible causes which may include cataract, glaucoma or rare diseases such as central serous chorioretinopathy (CSCR) which have been reported after use of systemic and topical corticosteroids.</p><p>Corticosteroid treatment has been associated with central serous chorioretinopathy, which is likely to result in retinal detachment.</p><p><strong>&nbsp;</strong></p><p><strong>Cardiac effects</strong></p><p>The adverse effects of glucocorticoids on the cardiovascular system, such as dyslipidaemia and hypertension, may predispose treated patients with existing cardiovascular risk factors to additional cardiovascular effects in cases of prolonged treatment at high doses. Accordingly, corticosteroids should be employed judiciously in such patients and attention should be paid to risk modification and additional cardiac monitoring if needed.<sup> </sup></p><p>In cases of congestive heart failure, systemic corticosteroids should be used with caution, and only if strictly necessary.</p><p><strong>&nbsp;</strong></p><p><strong>Vascular effects</strong></p><p>Thrombosis, including venous thromboembolic events, have been reported with the use of corticosteroids. Corticosteroids should therefore be used with caution in patients with thromboembolic disorders, or who may be predisposed to such disorders.</p><p><strong>&nbsp;</strong></p><p><strong>Gastrointestinal effects</strong></p><p>High doses of corticosteroids may cause acute pancreatitis.</p><p>&nbsp;</p><p>There is no universal agreement on whether corticosteroids per se are responsible for peptic ulcers encountered during treatment. However, glucocorticoid therapy may mask the symptoms of peptic ulcer so that perforation or haemorrhage may occur without significant pain. Treatment with a glucocorticoid may mask peritonitis or other signs or symptoms associated with gastrointestinal disorders, such as perforation, obstruction or pancreatitis. The risk of developing gastrointestinal ulcers increases in the event of combination with nonsteroidal anti-inflammatories.</p><p>&nbsp;</p><p>Corticosteroids should be used with caution in cases of nonspecific ulcerative colitis if there is an imminent risk of perforation, abscess or other pyogenic infection. Caution should also be exercised in cases of diverticulitis, recent intestinal anastomosis and active or latent peptic ulcer where steroids are used for either direct or adjuvant treatment.</p><p>&nbsp;</p><p><strong>Hepatobiliary effects</strong></p><p>Medicinal product-induced hepatic lesions, including acute hepatitis, or an increase in hepatic enzymes may be a result of the intravenous administration of methylprednisolone in cyclic intermittent treatment (usually at an initial dose of &ge; 1 g/day). Rare cases of hepatotoxicity have been reported. Its appearance may be delayed by several weeks or more. In the majority of case studies, these adverse reactions resolved after discontinuation of the treatment. Adequate monitoring is therefore required.</p><p>&nbsp;</p><p><strong>Musculoskeletal effects</strong></p><p>Acute myopathy has been reported with the use of high doses of corticosteroids, most often occurring in patients with neuromuscular transmission disorders (e.g. myasthenia gravis), or in patients receiving concomitant treatment with anticholinergics, such as neuromuscular blockers (e.g. pancuronium). This acute myopathy is generalised, may involve the ocular and respiratory muscles, and may result in quadriparesis. Elevations of creatine kinase may occur. Clinical improvement or recovery after discontinuation of corticosteroids may require weeks to years.</p><p>Osteoporosis is a common but infrequently recognised adverse effect associated with long-term use of large doses of glucocorticoids.</p><p>&nbsp;</p><p><strong>Renal and urinary disorders</strong></p><p>Caution is required in patients with systemic sclerosis because an increased incidence of scleroderma renal crisis has been observed with corticosteroids, including methylprednisolone.</p><p>&nbsp;</p><p>Corticosteroids should be used with caution in patients with renal insufficiency.</p><p><strong>&nbsp;</strong></p><p><strong>Investigations</strong></p><p>Average and large doses of hydrocortisone or cortisone may cause an increase in blood pressure, sodium and water retention and increased excretion of potassium. These effects are less likely to occur with synthetic derivatives, except when used in large doses. Dietary sodium restriction and potassium supplementation may be necessary. All corticosteroids increase calcium excretion.</p><p><strong>&nbsp;</strong></p><p><strong>Injury, poisoning and procedural complications</strong></p><p>&nbsp;&nbsp;&nbsp;&nbsp; Systemic corticosteroids are not indicated and should therefore not be used to treat traumatic brain injury. A multi-site study showed an increase in mortality at 2 weeks and at 6 months after injury in patients receiving methylprednisolone sodium succinate compared to those receiving placebo. A causal relationship with methylprednisolone sodium succinate has not been established.</p><p><strong>&nbsp;</strong></p><p><strong>Other </strong></p><p>Caution is recommended with prolonged corticosteroid treatment in the elderly, due to an increased risk of osteoporosis, as well as increased risk of fluid retention that may result in hypertension.</p><p>&nbsp;</p><p>Complications of treatment with glucocorticoids are dependent on the dose and duration of treatment. The risks must therefore be assessed against the benefits expected in each individual case, in order to determine the dose, duration of treatment and schedule of administration (daily or intermittent).</p><p>&nbsp;</p><p>Co-treatment with CYP3A inhibitors, including cobicistat-containing products, is expected to increase the risk of systemic side effects. The combination should be avoided unless the benefit outweighs the increased risk of systemic corticosteroid side effects, in which case patients should be monitored for systemic corticosteroid side effects (see section 4.5).</p><p>&nbsp;</p><p>Acetylsalicylic acid and nonsteroidal anti-inflammatories should be used with caution in patients taking corticosteroids.</p><p>In the interpretation of a number of biological tests and parameters (including skin tests and thyroid hormone concentration tests), any use of corticosteroids must be taken into account.</p><p>&nbsp;</p><p>Pheochromocytoma crisis, which can be fatal, has been reported after the administration of systemic corticosteroids. Corticosteroids should only be administered to patients with suspected or diagnosed pheochromocytoma after an appropriate risk/benefit assessment.</p><p>&nbsp;</p><p><em>&nbsp;</em></p><p>&nbsp;</p><p>&nbsp;</p><p><u>Pediatric population</u></p><p>The growth and development of infants and children receiving prolonged corticosteroid therapy should be carefully observed. In children receiving prolonged treatment with glucocorticoids in a fractioned daily dose, growth may be slowed. The use of such a regimen should be restricted to the most serious indications.</p><p>&nbsp;</p><p>Infants and children receiving prolonged corticosteroid therapy are exposed to a particular risk of raised intracranial pressure.<sup> </sup></p><p>&nbsp;</p><p>High doses of corticosteroids may result in pancreatitis in children.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Methylprednisolone, a substrate of cytochrome P450 (CYP) enzymes, is mainly metabolised by the CYP3A4 enzyme. CYP3A4 is the dominant enzyme of the most abundant CYP subfamily in the liver of adult humans. It catalyses 6&beta;-hydroxylation of steroids, the essential Phase I metabolic step for both endogenous and synthetic corticosteroids. Many other compounds are also substrates of CYP3A4, some of which (as well as other medicinal products) alter glucocorticoid metabolism by induction (upregulation) or inhibition of the CYP3A4 enzyme.</p><p>&nbsp;</p><p>CYP3A4 INHIBITORS such as ketoconazole, itraconazole, clarithromycin and grapefruit juice generally decrease hepatic clearance and increase the plasma concentration of methylprednisolone. In the presence of a CYP3A4 inhibitor, the dose of methylprednisolone may need to be reduced to avoid steroid toxicity.</p><p>&nbsp;</p><p>CYP3A4 INDUCERS such as rifampicin, carbamazepine, phenobarbital and phenytoin generally increase hepatic clearance and reduce the plasma concentration of methylprednisolone. In the presence of a CYP3A4 inducer, the dose of methylprednisolone may need to be increased to obtain the desired effect.<sup> </sup></p><p>&nbsp;</p><p>In the presence of another CYP3A4 substrate, the hepatic clearance of methylprednisolone may be affected. The dosage should therefore be adjusted. It is possible that adverse events associated with the use of either of these medicinal products alone may be more likely to occur with co-administration.</p><p>&nbsp;</p><p>Methylprednisolone also interacts with certain medicinal products unrelated to metabolism by CYP3A4.</p><p>&nbsp;</p><p><strong>Interactions/significant effects of the medicinal product or substance with methylprednisolone</strong></p><table border="1" cellspacing="0" cellpadding="0" style="width:637px"><thead><tr><td style="vertical-align:top"><p><strong>Class or type of medicinal product</strong></p><p><strong>&nbsp;&nbsp; - MEDICINAL PRODUCT or SUBSTANCE</strong></p></td><td style="vertical-align:top"><p><strong>Interaction or effect</strong></p></td></tr></thead><tbody><tr><td style="vertical-align:top"><p>Antibacterials</p><p>&nbsp;&nbsp;&nbsp;&nbsp; - ISONIAZID</p><p>&nbsp;</p></td><td style="vertical-align:top"><p>CYP3A4 INHIBITOR. A further potential effect of methylprednisolone is to increase acetylation rate and isoniazid clearance.<sup> </sup></p></td></tr><tr><td style="vertical-align:top"><p>Antibiotics, antituberculosis treatment</p><p>&nbsp;&nbsp; - RIFAMPICIN</p></td><td style="vertical-align:top"><p>CYP3A4 INDUCER</p></td></tr><tr><td style="vertical-align:top"><p>Anticoagulants (oral)</p><p>&nbsp;&nbsp;</p></td><td style="vertical-align:top"><p>The effect of methylprednisolone on oral anticoagulants varies. Reports mention both a decrease and an increase in the effects of anticoagulants in concomitant administration with corticosteroids. Therefore, coagulation rates should be checked in order to maintain the desired anticoagulant effects.</p></td></tr><tr><td style="vertical-align:top"><p>Anticonvulsants</p><p>&nbsp;&nbsp; - CARBAMAZEPINE</p></td><td style="vertical-align:top"><p>CYP3A4 INDUCER (and SUBSTRATE)</p></td></tr><tr><td style="vertical-align:top"><p>Anticonvulsants</p><p>&nbsp;&nbsp; - PHENOBARBITAL</p><p>&nbsp;&nbsp; - PHENYTOIN</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>CYP3A4 INDUCERS</p></td></tr><tr><td style="vertical-align:top"><p>Anticholinergics</p><p>&nbsp; - NEUROMUSCULAR BLOCKERS</p></td><td style="vertical-align:top"><p>Corticosteroids may influence the action of anticholinergics.</p><p>1) Acute myopathy has been observed during concomitant administration of high doses of corticosteroids and anticholinergics, such as neuromuscular blockers (see section 4.4, &ldquo;Musculoskeletal effects&rdquo; for further information).</p><p>2) Antagonism of the neuromuscular blocking effects of pancuronium and vecuronium has been reported in patients taking corticosteroids. This interaction may occur with all competitive neuromuscular blockers.</p></td></tr><tr><td style="vertical-align:top"><p>Cholinesterase inhibitors</p></td><td style="vertical-align:top"><p>Steroids may reduce the effects of cholinesterase inhibitors (such as neostigmine or pyridostigmine) in myasthenia gravis and may trigger an attack of myasthenia.</p></td></tr><tr><td style="vertical-align:top"><p>Antidiabetics</p></td><td style="vertical-align:top"><p>As corticosteroids may increase glycaemia, it may be necessary to adjust doses of antidiabetic agents.</p></td></tr><tr><td style="vertical-align:top"><p>Antiemetics&nbsp;</p><p>&nbsp;&nbsp; - APREPITANT</p><p>&nbsp;&nbsp; - FOSAPREPITANT</p></td><td style="vertical-align:top"><p>CYP3A4 INHIBITORS (and SUBSTRATES)<sup> </sup></p></td></tr><tr><td style="vertical-align:top"><p>Antifungals</p><p>&nbsp;&nbsp; - ITRACONAZOLE</p><p>&nbsp;&nbsp; - KETOCONAZOLE</p></td><td style="vertical-align:top"><p>CYP3A4 INHIBITOR (and SUBSTRATE)<sup> </sup></p></td></tr><tr><td style="vertical-align:top"><p>Antivirals</p><p>&nbsp;&nbsp; HIV PROTEASE INHIBITORS</p></td><td style="vertical-align:top"><p>CYP3A4 INHIBITOR (and SUBSTRATE)</p><p>1) HIV protease inhibitors, such as indinavir and ritonavir, may increase plasma concentrations of corticosteroids.</p><p>2) Corticosteroids may have an inductive effect on the metabolism of HIV protease inhibitors, causing a reduction in plasma concentrations.</p></td></tr><tr><td style="vertical-align:top"><p>Pharmacokinetic enhancers</p><p>&nbsp;&nbsp; - COBICISTAT</p></td><td style="vertical-align:top"><p>CYP3A4 INHIBITORS</p><p>Pharmacokinetic enhancers inhibit the activity of CYP3A4 resulting in a decrease of the hepatic clearance and an increase of the plasma concentrations of corticosteroids. A corticosteroid dose adaptation may be necessary (see section 4.4).</p></td></tr><tr><td style="vertical-align:top"><p>Aromatase inhibitor - AMINOGLUTETHIMIDE</p></td><td style="vertical-align:top"><p>The adrenal suppression induced by aminoglutethimide may exacerbate the endocrine changes caused by prolonged treatment with glucocorticoids.</p></td></tr><tr><td style="vertical-align:top"><p>Calcium antagonists</p><p>&nbsp;&nbsp; - DILTIAZEM</p></td><td style="vertical-align:top"><p>CYP3A4 INHIBITOR (and SUBSTRATE)</p></td></tr><tr><td style="vertical-align:top"><p>Contraceptives (oral)</p><p>- ETHINYL ESTRADIOL / NORETHINDRONE&nbsp;&nbsp;&nbsp;</p></td><td style="vertical-align:top"><p>CYP3A4 INHIBITOR (and SUBSTRATE)<sup> </sup></p><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; - GRAPEFRUIT JUICE</p></td><td style="vertical-align:top"><p>CYP3A4 INHIBITOR</p></td></tr><tr><td style="vertical-align:top"><p>Immunosuppressants</p><p>&nbsp;&nbsp; - CICLOSPORIN</p><p>&nbsp;&nbsp;</p></td><td style="vertical-align:top"><p>CYP3A4 INHIBITOR (and SUBSTRATE)</p><p>1) Concomitant administration of ciclosporin and methylprednisolone causes reciprocal inhibition of their metabolism, which may increase plasma concentrations of one or both substances. The undesirable effects associated with the use of each medicinal product alone may therefore be increased in cases of concomitant administration.</p><p>2) Convulsions have been observed during simultaneous administration of methylprednisolone and ciclosporin.<sup> </sup></p></td></tr><tr><td style="vertical-align:top"><p>Immunosuppressants</p><p>&nbsp;- CYCLOPHOSPHAMIDE</p><p>- TACROLIMUS</p></td><td style="vertical-align:top"><p>CYP3A4 SUBSTRATE</p></td></tr><tr><td style="vertical-align:top"><p>Macrolide antibiotics</p><p>&nbsp;- CLARITHROMYCIN</p><p>- ERYTHROMYCIN</p></td><td style="vertical-align:top"><p>CYP3A4 INHIBITOR (and SUBSTRATE)<sup> </sup></p></td></tr><tr><td style="vertical-align:top"><p>Macrolide antibiotics</p><p>&nbsp;&nbsp; - TROLEANDOMYCIN</p></td><td style="vertical-align:top"><p>CYP3A4 INHIBITOR</p></td></tr><tr><td style="vertical-align:top"><p>NSAIDs (nonsteroidal anti-inflammatory drugs)</p><p>&nbsp;&nbsp; - High doses of acetylsalicylic acid</p><p>&nbsp;</p></td><td style="vertical-align:top"><p>1) In cases of concomitant administration of corticosteroids and NSAIDs, the incidence of gastrointestinal haemorrhage and ulcerations may increase.</p><p>2) Methylprednisolone may increase the clearance of acetylsalicylic acid administered at high doses, which may cause a reduction in serum salicylate levels. Discontinuation of methylprednisolone treatment may cause an increase in serum salicylate levels, which may cause increased risk of salicylate toxicity.</p><p>3) In cases of hypoprothrombinaemia, caution should be exercised in the use of acetylsalicylic acid during corticosteroid treatment.</p></td></tr><tr><td style="vertical-align:top"><p>Agents that increase potassium loss</p></td><td style="vertical-align:top"><p>In cases of concomitant administration of corticosteroids and agents that increase potassium loss (e.g. thiazides and related, loop diuretics), patients should be closely monitored to avoid hypokalaemia.&nbsp; The combination of glucocorticoids and thiazide diuretics increases the risk of glucose intolerance.</p><p>There is also an increased risk of hypokalaemia in cases of concomitant use of corticosteroids and amphotericin B, xanthenes or beta<sub>2</sub>-mimetics.</p></td></tr><tr><td style="vertical-align:top"><p>Antibacterials</p><p>- Quinolones</p></td><td style="vertical-align:top"><p>The risk of tendinitis is increased with concomitant administration of quinolones.</p></td></tr><tr><td style="vertical-align:top"><p>Antihypertensives</p></td><td style="vertical-align:top"><p>Simultaneous administration of antihypertensives may cause partial loss of control of hypertension, as the mineralocorticoid effect of corticosteroids can bring about an increase in blood pressure.</p></td></tr><tr><td style="vertical-align:top"><p>Cardiotonic glycosides</p><p>- DIGOXIN</p></td><td style="vertical-align:top"><p>The toxicity of cardiotonic glycosides, such as digoxin and related substances, may increase in cases of simultaneous use with corticosteroids, as the mineralocorticoid effect may induce potassium loss.</p></td></tr><tr><td style="vertical-align:top"><p>Methotrexate</p></td><td style="vertical-align:top"><p>Methotrexate may influence the effect of methylprednisolone via a synergistic effect on the pathological condition. A dose reduction of the corticosteroid may be considered.</p></td></tr><tr><td style="vertical-align:top"><p>Sympathomimetics&nbsp;</p></td><td style="vertical-align:top"><p>Methylprednisolone may increase the response to sympathomimetics such as salbutamol. This may increase both the efficiency and the potential toxicity of sympathomimetics.</p></td></tr><tr><td style="vertical-align:top"><p>Phenylbutazone</p></td><td style="vertical-align:top"><p>Simultaneous administration of phenylbutazone may induce metabolism of corticosteroids, and therefore reduce their activity.</p></td></tr><tr><td style="vertical-align:top"><p>Vaccines</p></td><td style="vertical-align:top"><p>The administration of live attenuated vaccines is not recommended in patients receiving immunosuppressive doses of corticosteroids. Inactivated vaccines and biogenetically produced vaccines may however be administered to these patients, but the therapeutic response to these vaccines may be reduced or even ineffective. In patients receiving non-immunosuppressive doses of corticosteroids, the necessary immunisation procedures may be undertaken (see section 4.4).</p></td></tr></tbody></table><p>&nbsp;</p><p>In the treatment of neoplastic diseases such as leukaemia and lymphoma, methylprednisolone is typically used in combination with alkylating agents, antimetabolites and vinca alkaloids.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>Pregnancy</strong></p><p>There are no or limited amount of data from the use of methylprednisolone acetate in pregnant women. Corticosteroids do not appear to cause congenital anomalies when given to pregnant women.</p><p>In the absence of adequate studies of the effects of methylprednisolone on human reproduction, this medicinal product should only be used during pregnancy following careful evaluation of the ratio of benefits to risks for the mother and the foetus.</p><p>&nbsp;</p><p>Corticosteroids readily cross the placenta. A retrospective study found an increased incidence of low birth weight in infants born to mothers receiving corticosteroids. In humans, the risk of low birth weight appears to be linked to the dose, and may be minimised by the administration of the lowest dose of corticosteroids.</p><p>&nbsp;</p><p>Neonates whose mothers have been treated with large amounts of corticosteroids during pregnancy should be closely monitored for symptoms of adrenal insufficiency, although neonatal adrenal insufficiency appears to be rare in infants exposed to corticosteroids in utero.</p><p>&nbsp;</p><p>Cases of cataracts have been observed in infants born to mothers taking corticosteroids in the long term during pregnancy.</p><p>Studies in animals have shown reproductive toxicity (see section 5.3).</p><p>&nbsp;</p><p>If long-term treatment with corticosteroids needs to be discontinued during pregnancy (as with other chronic treatments), this should occur gradually (see section 4.2). In certain cases (replacement therapy in adrencortical insufficiency, for example), it may be necessary to continue the treatment, or even to increase the dose.</p><p>&nbsp;</p><p><strong>Lactation</strong></p><p>Corticosteroids are excreted in human milk.</p><p>&nbsp;</p><p>Corticosteroids excreted in human milk may inhibit growth and disturb production of endogenous glucocorticoids in breast-fed infants. This medicinal product should only be used while breastfeeding following careful evaluation of the ratio of benefits to risks for the mother and the infant.</p><p><strong>&nbsp;</strong></p><p><strong>Fertility </strong></p><p>Studies in animals have shown that corticosteroids alter fertility (see section 5.3).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The effect of corticosteroids on the ability to drive and use machines has not been systematically studied. Undesirable effects such as dizziness, vertigo, visual disturbances and fatigue are possible after treatment with corticosteroids. If affected, patients should not drive or use machines.</p><p>Although visual disorders are a rare undesirable effect, patients driving vehicles and/or using machines should be informed of these adverse reactions.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Safety profile summary</u></p><p>The following undesirable effects are typical of systemic corticosteroids. Hypersensitivity reactions to medicinal products may occur at the start of treatment. Serious infections, including opportunistic infections, may also occur during treatment with corticosteroids. The other adverse medicinal product reactions are as follows: convulsions, pathological and spinal compression fractures, peptic ulcers with perforation or haemorrhage, tendon rupture, psychiic or psychotic disorders, Cushingoid disorders, glucose intolerance disorders, steroid withdrawal syndrome, hypertension, myopathy, glaucoma, cataract, rash, fluid retention, abdominal pain, nausea, headaches and dizziness.</p><p>&nbsp;</p><p><u>Table of undesirable effects</u></p><p>General undesirable effects may be observed. These rarely occur during treatment of very short duration, but should nevertheless be carefully monitored. This is an inherent aspect of all corticosteroid treatment and is therefore in no way specific to a particular product.</p><p>&nbsp;</p><p>Glucocorticoids such as methylprednisolone may have the following systemic side effects:</p><p>&nbsp;</p><p>The following undesirable effects are listed according to MedDRA system organ class and in order of frequency:</p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><thead><tr><td style="vertical-align:top"><p><strong>System organ class</strong></p></td><td style="vertical-align:top"><p><strong>Frequency not known</strong></p><p><strong>(cannot be estimated from the available data)</strong></p><p><strong>&nbsp;</strong></p></td></tr></thead><tbody><tr><td style="vertical-align:top"><p><strong>Infections and infestations</strong></p></td><td style="vertical-align:top"><p>Opportunistic infection, infection, infection at the injection site, peritonitis<sup>*</sup>.</p></td></tr><tr><td style="vertical-align:top"><p><strong>Blood and lymphatic system disorders</strong></p></td><td style="vertical-align:top"><p>Leucocytosis.</p></td></tr><tr><td style="vertical-align:top"><p><strong>Immune system disorders</strong></p></td><td style="vertical-align:top"><p>Medicinal product hypersensitivity, anaphylactic reaction, anaphylactoid reaction.</p></td></tr><tr><td style="vertical-align:top"><p><strong>Endocrine disorders</strong></p></td><td style="vertical-align:top"><p>Cushingoid syndrome, hypopituitarism, steroid withdrawal syndrome.</p></td></tr><tr><td style="vertical-align:top"><p><strong>Metabolism and nutrition disorders</strong></p></td><td style="vertical-align:top"><p>Metabolic acidosis, epidural lipomatosis, sodium retention, fluid retention, hypokalaemic alkalosis, dyslipidaemia, glucose intolerance disorders, increase in insulin needs (or those of oral glucose-lowering agents in diabetics), lipomatosis, increase in appetite (which may cause weight gain).</p></td></tr><tr><td style="vertical-align:top"><p><strong>Psychiatric disorders</strong></p></td><td style="vertical-align:top"><p>Affective disorders (including depressed mood, euphoric mood, affective lability, psychological dependence, suicidal ideation), psychotic disorders (including mania, delirium, hallucinations and schizophrenia), mental disorders, changes in personality, confusion, anxiety, mood swings, behavioural disorders, insomnia, irritability.</p></td></tr><tr><td style="vertical-align:top"><p><strong>Nervous system disorders</strong></p></td><td style="vertical-align:top"><p>Increase in intracranial tension (with papillary oedema [benign intracranial hypertension]), seizures, amnesia, cognitive disorder, sensation of dizziness, headache.</p></td></tr><tr><td style="vertical-align:top"><p><strong>Eye disorders</strong></p></td><td style="vertical-align:top"><p>Chorioretinopathy, rare cases of blindness associated with intralesional treatment in the face and head region, cataract, glaucoma, exophthalmia, vision, blurred (see also section 4.4).</p></td></tr><tr><td style="vertical-align:top"><p><strong>Earand labyrinth disorders</strong></p></td><td style="vertical-align:top"><p>Dizziness.</p></td></tr><tr><td style="vertical-align:top"><p><strong>Cardiac disorders</strong></p></td><td style="vertical-align:top"><p>Congestive heart failure (in susceptible patients).</p></td></tr><tr><td style="vertical-align:top"><p><strong>Vascular disorders</strong></p></td><td style="vertical-align:top"><p>Thrombotic events, hypertension, hypotension.</p></td></tr><tr><td style="vertical-align:top"><p><strong>Respiratory, thoracic and mediastinal disorders</strong></p></td><td style="vertical-align:top"><p>Pulmonary embolism, persistent hiccups.</p></td></tr><tr><td style="vertical-align:top"><p><strong>Gastrointestinal disorders</strong></p></td><td style="vertical-align:top"><p>Peptic ulcer (with possibility of perforation or haemorrhage of the peptic ulcer), intestinal perforation, gastric haemorrhage, pancreatitis, ulcerous oesophagitis, oesophagitis, abdominal pain, abdominal distension, diarrhoea, dyspepsia, nausea, vomiting.</p></td></tr><tr><td style="vertical-align:top"><p><strong>Hepatobiliary disorders</strong></p></td><td style="vertical-align:top"><p>Hepatitis, increase in liver enzymes (e.g. AST, ALT)</p></td></tr><tr><td style="vertical-align:top"><p><strong>Skin and subcutaneous tissue disorders</strong></p></td><td style="vertical-align:top"><p>Angio-oedema, hirsutism, petechiae, ecchymosis, cutaneous atrophy, erythema, hyperhidrosis, cutaneous striae, rash, pruritus, urticaria, acne, cutaneous hyperpigmentation, cutaneous hypopigmentation.</p></td></tr><tr><td style="vertical-align:top"><p><strong>Musculoskeletal and connective tissue disorders</strong></p></td><td style="vertical-align:top"><p>Muscle weakness, myalgia, myopathy, muscle atrophy,</p><p>osteoporosis, osteonecrosis, pathological fractures, neuropathic arthropathy, arthralgia, growth disorder.</p></td></tr><tr><td style="vertical-align:top"><p><strong>Reproductive system and breast disorders</strong></p></td><td style="vertical-align:top"><p>Menstrual irregularity.</p></td></tr><tr><td style="vertical-align:top"><p><strong>General disorders and administration site conditions</strong></p></td><td style="vertical-align:top"><p>Sterile abscess, delayed healing, peripheral oedema, fatigue, malaise, reaction at the injection site.</p></td></tr><tr><td style="vertical-align:top"><p><strong>Investigations</strong></p></td><td style="vertical-align:top"><p>Increase in intraocular pressure, reduced tolerance to carbohydrates, reduced kalaemia, increased calcium in the urine, increased blood alkaline phosphatase, increased blood urea, suppression of reactions to skin tests.</p></td></tr><tr><td style="vertical-align:top"><p><strong>Injury, poisoning and procedural complications</strong></p></td><td style="vertical-align:top"><p>Tendon rupture (especially the Achilles tendon), vertebral compression fractures.</p></td></tr></tbody></table><p>* Peritonitis may be the main sign or symptom of the onset of a gastrointestinal disorder, such as perforation, obstruction or pancreatitis (see section 4.4).</p><p>&nbsp;</p><p><strong>In situ administration</strong></p><p>As the medicinal product is absorbed from the administration site into the general circulation, the general undesirable effects mentioned above should be taken into account.</p><p>In cases of local administration, dermal and subdermal atrophy may also occur. Although corticosteroid crystals can inhibit inflammatory reactions in the skin, their presence may cause a disintegration of cellular elements and physiological changes to the fundamental substance of the connective tissue. The resulting dermal and subdermal alterations can cause cutaneous depressions at the injection site.</p><p>The extent of this reaction depends on the quantity of corticosteroid injected (see section 4.4). Regeneration is usually complete after a few months, or once the corticosteroid crystals have been entirely absorbed.</p><p>&nbsp;</p><p><strong>Adverse reactions reported with certain contraindicated routes of administration: </strong></p><p><u>Intrathecal/epidural routes</u>: arachnoiditis, functional gastrointestinal disorder/bladder dysfunction, headache, meningitis, paraparesis/paraplegia, seizures, sensory disturbances. The frequency of these undesirable effects is not known.</p><p><u>Intranasal route</u><br />Temporary or permanent visual disorders, possibly leading to blindness; allergic reactions; rhinitis.</p><p><u>Ophthalmic route</u><br />Temporary or permanent visual disorders, possibly leading to blindness; increased intraocular pressure, ocular and periocular inflammation and allergic reactions, infections, residue or atrophy at the injection site.</p><p><u>Various injection sites </u><br />(scalp, oropharynx, sphenopalatine ganglion): blindness.</p><p>&nbsp;</p><p><strong>Paediatric population</strong></p><p>The frequency, type and severity of most of the undesirable effects is expected to be the same as in adults, except for mood swings, behavioural disorders and insomnia, which are more common in children.</p><p>&nbsp;</p><p><strong>Reporting of suspected adverse reactions:</strong></p><p>Reporting suspected adverse reactions after market authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via national reporting system</p><p>&nbsp;</p><p><strong>To Report side effects</strong></p><ul><li>Saudi Arabia</li></ul><p>&nbsp;</p><table border="0" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>National Pharmacovigilance Centre ( NPC )</p><ul><li>Call center: 19999</li><li>E-mail: npc.drug@sfda.gov.sa</li><li>Website: https://ade.sfda.gov.sa/&nbsp;&nbsp;</li></ul><p>&nbsp;</p><p>&nbsp;</p></td></tr></tbody></table>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Symptoms:</u></p><p>No clinical syndrome of acute overdose with methylprednisolone acetate has been reported.</p><p>&nbsp;</p><p><u>Management:</u></p><p>Cases of acute intoxication and/or death following overdose of corticosteroids are rare. In the event of an overdose, no specific antidote is available; treatment is supportive and symptomatic.</p><p>&nbsp;</p><p>Methylprednisolone is dialysable.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacotherapeutic group: glucocorticoids, ATC&nbsp;code: H02AB04</p><p>&nbsp;</p><p><u>Mechanism of action</u></p><p>Depo-Medrol is a sterile injectable suspension of methylprednisolone acetate, a synthetic glucocorticoid with powerful and long-lasting anti-inflammatory, immunosuppressive and anti-allergic effects, and has a more potent anti-inflammatory effect than prednisolone. In addition, Depo-Medrol is less likely to cause water and sodium retention than prednisolone. Depo-Medrol may also be administered intramuscularly for prolonged systemic action, or in situ for local treatment. The prolonged activity of Depo-Medrol is explained by the slower release of the active substance.</p><p>&nbsp;</p><p>Methylprednisolone acetate has the general properties of the glucocorticoid methylprednisolone but is less soluble and is metabolised more slowly, which explains its long duration of action.</p><p>Glucocorticoids diffuse across cell membranes and form complexes with specific receptors in the cytoplasm. These complexes then enter the cell nucleus, bind to DNA (chromatin), and promote the transcription of mRNA and the consecutive synthesis of various enzymes that are ultimately responsible for the varied effects observed in the systemic use of glucocorticoids. In addition to their significant effect on the inflammatory and immune process, glucocorticoids also affect the metabolism of carbohydrates, proteins and fats. They also have an effect on the cardiovascular system, the skeletal muscles and the central nervous system.</p><p>&nbsp;</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Effect on the inflammatory and immune process:<br />The anti-inflammatory, immunosuppressive and anti-allergic properties of glucocorticoids are the basis of a very substantial number of their therapeutic applications. The main aspects of these properties are as follows:</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Decrease in immunoactive cells in the source of the inflammation;</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Decreased vasodilation;</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Stabilisation of lysosomal membranes;</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Inhibition of phagocytosis;</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Reduced production of prostaglandins and related substances.</p><p>A dose of 4.4 mg methylprednisolone acetate (4 mg methylprednisolone) has a glucocorticoid (anti-inflammatory) effect equivalent to a dose of 20 mg hydrocortisone.</p><p>Methylprednisolone has a minimal mineralocorticoid effect (200 mg methylprednisolone is equivalent to 1 mg deoxycorticosterone).</p><p>&nbsp;</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Effect on the metabolism of carbohydrates and proteins:<br />Glucocorticoids stimulate protein catabolism. In the liver, the amino acids released are converted into glucose and glycogen by the process of gluconeogenesis. The absorption of glucose into the peripheral tissue reduces, which leads to hyperglycaemia and glycosuria, especially in patients predisposed to diabetes.</p><p>&nbsp;</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Effect on lipid metabolism:<br />Glucocorticoids have a lipolytic action. This lipolysis is most pronounced in the limbs. They also have an effect on the lipogenesis in the torso, neck and head. All of these effects result in the redistribution of fat deposits.</p><p>&nbsp;</p><p><u>Pharmacodynamic effects</u></p><p>The maximum pharmacological activity of glucocorticoids is attained later than peak plasma concentrations, suggesting that the principal effects of these substances are not based on direct medicinal action, but on changes in enzyme activity.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Methylprednisolone acetate is hydrolysed to its active form by plasma cholinesterase. In humans, methylprednisolone binds weakly to albumin and globulin. Approximately 40 to 90% of the medicinal product is bound to proteins. The intracellular activity of glucocorticoids results in a significant difference between the plasma half-life and pharmacological half-life. Pharmacological activity persists after plasma concentrations have ceased to be measurable.</p><p>&nbsp;</p><p>The duration of the anti-inflammatory activity of glucocorticoids is very close to the duration of inhibition of the hypothalamic-pituitary-adrenal (HPA) axis.</p><p>After approximately 7.3 &plusmn; 1 hours (Tmax), an IM injection of 40 mg/mL results in a peak plasma concentration of methylprednisolone of approximately 1.48 &plusmn; 0.86 &micro;g/100 mL (Cmax). The half-life in this case is 69.3 hours. After IM administration of a single dose of 40 to 80 mg of methylprednisolone acetate, the HPA axis may be inhibited for 4 to 8 days.</p><p>After 4 to 8 hours, an intra-articular injection of 40 mg into both knees (total dose 80 mg) results in a peak plasma concentration of methylprednisolone of approximately 21.5 &micro;g/100 mL. After intra-articular injection, the duration of both HPA axis inhibition and plasma concentrations of methylprednisolone demonstrate that methylprednisolone acetate diffuses into to the bloodstream from the joints for a period of approximately 7 days.</p><p>&nbsp;</p><p>Methylprednisolone is metabolised at hepatic level, qualitatively similarly to cortisol. The main metabolites are 20-beta-hydroxymethylprednisolone and 20-beta-hydroxy-6-alpha-methylprednisolone. The metabolites are principally excreted in the urine as glucuronides, sulphates and unconjugated compounds. These conjugation reactions occur primarily in the liver, and to a certain extent in the kidneys.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Conventional studies of safety pharmacology, repeated dose toxicity reveal no special hazard. The toxicities observed in repeated dose studies are as expected during continuous exposure to exogenous adrenocortical steroids.</p><p>&nbsp;</p><p><u>Carcinogenic potential: </u></p><p>Methylprednisolone has not been formally evaluated in carcinogenicity studies on rodents. Other glucocorticoids have been tested for carcinogenicity on mice and rats with variable results. However, published data indicates that several similar glucocorticoids, in particular, budesonide, prednisolone and triamcinolone acetonide, may increase the incidence of adenomas and hepatocellular carcinomas after oral administration in the drinking water of male rats. These carcinogenic effects occurred at doses lower than the usual clinical doses expressed in mg/m<sup>2</sup>.</p><p>&nbsp;</p><p><u>Mutagenic potential</u>:</p><p>No potential of genetic and chromosomal mutations has been demonstrated in the limited studies conducted on bacterial and mammal cells.<br /><br /><u>Reproductive toxicity:</u></p><p>It has been demonstrated that corticosteroids administered to rats reduce fertility. In rats, corticosterone induced a reduction in seminal plugs, the number of implantations and viable foetuses.</p><p>&nbsp;</p><p>Corticosteroids have been shown to be teratogenic in many species after administration of doses equivalent to the human dose. In reproductive studies in animals, glucocorticoids such as methylprednisolone were found to induce malformations (cleft palate, skeletal malformations) and delayed intrauterine growth.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Macrogol 3350; myristyl-gamma-picolinium chloride; sodium chloride; water for injection.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Due to possible physical incompatibilities, Depo-Medrol should not be diluted or mixed with other solutions.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Do not use Depo Medrol after the expiry date which is stated on the carton label after EXP: The expiry date refers to the last day of that month.

 Shelf life 36 months

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Store below 30C.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Depo-Medrol 40 mg/1 mL suspension for injection (40 mg/mL) is available in packs containing one 1&nbsp;mL vial(s).).<br />Depo-Medrol 80 mg/2 mL suspension for injection (40 mg/mL) is available in packs containing one 2 mL vial.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Before use, the medicinal products administered parenterally should be inspected visually in order to detect the possible presence of particles or discolouration. Strict aseptic technique is essential to prevent iatrogenic infections. This product is not suitable for intravenous, intrathecal, epidural,&nbsp; intranasal, ophthalmic administration or administration at various injection sites (scalp, oropharynx, sphenopalatine ganglion). Do not use this vial for more than one dose. After administration of the desired dose, the remaining suspension must be discarded.</p><p>&nbsp;</p><p>How to use the syringe:</p><p>Shake the vial well before use to obtain a uniform suspension.</p><p>1. Remove the protective cap</p><p>2. Place the needle on the syringe</p><p>3.&nbsp; Remove the protective needle guard. The syringe is ready for use.</p><p>&nbsp;</p><p>&nbsp;</p><p><!--[if gte vml 1]><v:shapetype id="_x0000_t75"
 coordsize="21600,21600" o:spt="75" o:preferrelative="t" path="m@4@5l@4@11@9@11@9@5xe"
 filled="f" stroked="f">
 <v:stroke joinstyle="miter"/>
 <v:formulas>
  <v:f eqn="if lineDrawn pixelLineWidth 0"/>
  <v:f eqn="sum @0 1 0"/>
  <v:f eqn="sum 0 0 @1"/>
  <v:f eqn="prod @2 1 2"/>
  <v:f eqn="prod @3 21600 pixelWidth"/>
  <v:f eqn="prod @3 21600 pixelHeight"/>
  <v:f eqn="sum @0 0 1"/>
  <v:f eqn="prod @6 1 2"/>
  <v:f eqn="prod @7 21600 pixelWidth"/>
  <v:f eqn="sum @8 21600 0"/>
  <v:f eqn="prod @7 21600 pixelHeight"/>
  <v:f eqn="sum @10 21600 0"/>
 </v:formulas>
 <v:path o:extrusionok="f" gradientshapeok="t" o:connecttype="rect"/>
 <o:lock v:ext="edit" aspectratio="t"/>
</v:shapetype><v:shape id="Picture_x0020_1" o:spid="_x0000_i1025" type="#_x0000_t75"
 style='width:447pt;height:57pt;visibility:visible'>
 <v:imagedata src="file:///C:/Users/ibrahw02/AppData/Local/Temp/1/msohtmlclip1/01/clip_image001.png"
  o:title=""/>
</v:shape><![endif]--><img width="596" height="76" src="file:///C:/Users/ibrahw02/AppData/Local/Temp/1/msohtmlclip1/01/clip_image002.jpg" /></p><p>&nbsp;</p><p>&nbsp;</p><p>After use, the syringe must be discarded and must not be reused.</p><p>&nbsp;</p><p>Any unused medicinal product or waste material should be disposed of in accordance with local requirements.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                MARKETING AUTHORISATION HOLDER 

Pfizer S.A., Boulevard de la Plaine 17, Brussels, Belgium. 


MANUFACTURER :

 Pfizer Manufacturing Belgium N.V, Rijsweg 12, Puurs, Belgium

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                January 2021
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>